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Abstract 
The objective of this study is to characterize the role of MK2 in experimental autoimmune 
encephalomyelitis (EAE), an animal model for multiple sclerosis (MS). Inflammatory 
demyelination in the CNS is the pathological hallmark of MS. MK2 is an essential 
component in the inflammatory response, which regulates biosynthesis of TNF-α at a 
post-transcriptional level. We hypothesized that MK2 is a negative regulator in EAE. The 
previous study done in our lab underlines the significance of MK2 in the regulation of 
CNS inflammatory disease, multiple sclerosis and its animal model, EAE. The initial 
hypothesis was rejected in the study as MK2 deficiency resulted in a more severe disease 
course and was associated with more cellular CNS inflammation.  
Yet, this study is the first to characterize the morphology, histology and distribution of 
immune cells in spinal cord lesions of MOG35-55-EAE of MK2
-/- mice. MOG35-55 peptide 
was used to induce EAE in 10-12 weeks old MK2-/- and control female mice. No 
phenotypic changes were observed in MK2-/- mice. The clinical symptoms were seen 
from day 9-11 after the induction. The MK2-/- mice showed milder symptoms of     
MOG35-55-EAE on day 12 and day 14, the acute phase of EAE. Histological analysis of 
the acute phase EAE showed reduced inflammation, reduced total myelin loss and axonal 
loss. Acute phase EAE was associated with some regulations, however, no pattern was 
seen in the chronic phase EAE. These findings suggest that MK2 might not serve as a 
potential target in the treatment of EAE model. 
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1 Introduction 
1.1 Multiple sclerosis 
There have been descriptions of multiple sclerosis (MS) since the 14th century. It was, 
Jean-Martin Charcot (1825–1893) the French neurologist, who made the first definite 
connections between the symptoms of MS and the pathological changes seen in post-
mortem samples (Lublin & Reingold, 1996). The first recognizable case of multiple 
sclerosis appears to be that of Augustus d’Este (1794–1848), the grandson of George III 
of England and cousin of Queen Victoria (Weiner, 2005). This ambiguous, relapsing and 
progressive disorder of the central nervous system continues to be challenging in not only 
understanding the pathogenesis of the disease but also its prevention and progression. The 
course of MS is highly diverse and unpredictable. With around 2.5 million worldwide 
and 120,000 people affected in Germany alone, billions of dollars are spend in health care 
costs. Women are affected twice as much by MS as men and persons of Northern 
European descent appear to be at a higher risk for MS (Brust, 2007; Hauser SL, 2008). 
MS typically occurs in adults aged 20 to 45 years; occasionally, it may also be present in 
childhood or late middle age (Brust, 2007). The cause of MS still remains unknown, but 
the current knowledge points to the involvement of combination of genetic susceptibility 
and a non-genetic trigger, such as virus, changes in metabolism or environmental factors. 
When that is put together it results in this autoimmune disorder that leads to recurrent 
immune attacks on the CNS (Brust, 2007). 
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Figure 1  World distribution of multiple sclerosis: greater prevalence in higher northern and southern latitudes. 
(Source: WHO MS Atlas) 
1.1.1 Etiology of MS 
The primary cause of damage in MS is the inflammation of central nervous system. 
Previous studies suggested that genetic, environmental and infectious agents can be some 
of the factors influencing the development of MS (Loma & Heyman, 2011). Studies with 
families and twin have shown a 40-fold increase in susceptibility amongst first-degree 
relatives of MS patients, which suggests a genetic basis for a risk to develop MS (Loma 
& Heyman, 2011). Environmental factors, such as exposure to infectious agents as well 
as sunlight exposure/vitamin D can be accounted for risk of MS. The risk persists even 
when a person migrates from one risk area to another before the age of 15 years (Milo & 
Kahana, 2010). The infectious agents known to be possibly involved are human herpes 
virus type 6, Epstein Barr virus and mycoplasma pneumonia (Fujinami, von Herrath, 
Christen, & Whitton, 2006).  
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1.1.2 MS symptoms and pathology 
The symptoms of MS are varied and differ from patient to patient, but some patterns are 
usually the same and can be defined (Compston & Coles, 2008). The most commonly 
affected sites, which show significant symptoms are the optic nerves, the cerebrum and 
the spinal cord. Patients can be manifested with a distinct number of symptoms including 
changes in vision (unilateral visual loss, diplopia), weakness, discoordination, distortions 
or changes in bowel and bladder function. There are other array of symptoms as well 
which have less diagnostic value; these include cognitive change, fatigue and mood 
disturbances. So many varied symptoms and progression of this disease may eventually 
lead to severe disability (Loma & Heyman, 2011).  
 
 
Figure 2: Major symptoms of multiple sclerosis. (Image by J.Oksenberg/UCSF) 
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The conventional view of explaining the sequence of events that occur in MS start with 
activation of myelin reactive T-cells which migrate from the periphery into the CNS. This 
leads to inflammation and development of focal demyelinating lesions, which is the main 
pathological feature for relapses. The progressive phase of MS consists of axonal 
degeneration with neuronal loss. Previous pathological studies have shown that 
throughout the normal appearing white matter, axonal degeneration occurs diffusely 
(Mahad, Trapp, & Lassmann, 2015). Conduction block is the major cause of the negative 
symptoms during relapses that range from paralysis, blindness to numbness. This is 
caused largely by inflammation and demyelination and possibly by defects in synaptic 
transmission. In remission the recovery from symptoms is mainly due to the restoration 
of axonal function. This restoration is either because of remyelination, the settlement of 
inflammation or the restoration of conduction to axons. These impairments persist in the 
demyelinated state which in turn contributes to weakness and sensory problems (K. J. 
Smith & McDonald, 1999). 
 
Figure 3: The inflammation phase of multiple sclerosis. Transcriptional analysis of targets in multiple sclerosis 
(Steinman & Zamvil, 2003) 
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MS is primarily an inflammatory disease of the CNS in which auto-aggressive T-cells 
cross the blood-brain barrier (BBB) causing demyelination and axonal loss resulting in 
progressive disability (Ortiz et al., 2014). The inflammatory process is started by 
autoimmune T-cells reaction that targets myelin antigens, which can be initiated trough 
molecular mimicry mechanisms (Karussis, 2014). There are numerous other cell types 
and cell subsets that are also involved, like T helper 17 (Th17) cells (McFarland & Martin, 
2007). Pro-inflammatory cytokines like IL-17, IL-6  are secreted by these T-cells (Th17) 
and are regulated by IL-23 (Langrish et al., 2005; Steinman, 2007). A transition from 
physiological surveillance to a pathological immune response occurs when these 
inflammatory cells and other cell types become deregulated, which is when the disease 
occurs (Compston & Coles, 2008; Dolei et al., 2014) 
There are studies from thsions of MS patients confirming an overwhelming presence of 
CD4+ cells secreting IL-17 in active lesions. In MS lesions though, both CD4+ and 
CD8+cells express IL-17 (Tzartos et al., 2008).  
Chemokine receptor CCR6 expressed on Th17 cells interacts with CCL20/MIP-3α 
expressed on endothelium, it facilitates transport through the choroid plexus into the CSF 
and perivascular space (Reboldi et al., 2009). GM-CSF might also be produced by Th17 
cells, this can be promoted by resident antigen presenting cells (APCs) secreting IL-23. 
This initiates a positive feedback loop as the same APCs are stimulated by GM-CSF 
(Codarri et al., 2011; Dolei et al., 2014; El-Behi et al., 2011). Also, by disrupting the 
endothelial tight junctions the Th17 cells may further increase permeability of the BBB 
due to the secretion of IL-17 and IL-22. This allows interactions with endothelium, which 
allows further attraction of CD4+ subsets as well as other immune cells. Consequently a 
pathological sequence is initiated; consisting of inflammation, infiltrates and damage to 
neurons and glia cells (Dolei et al., 2014; Tzartos et al., 2008). 
Myelin destruction is the essential component of the plaques within the CNS. The MS 
plaques are not simply an inflammatory demyelinating entity in isolation; rather lesions 
are composed of wide variety of immunological and pathological entities. There is a close 
relation of cellular and molecular components, time of damage and repair systems to 
myelin loss and axonal injury. Thus, it is important to understand the various features of 
plaque development as they provide a mechanism to understand the pathogenic 
mechanisms underlying MS. 
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MS plaques are classified based on the stages and the time for progression of 
inflammatory destruction. There are acute, chronic acute and chronic silent lesions. 
Studies have shown that these lesions occur along a continuous timeline, they eventually 
scar and harden the areas within the CNS. Acute plaques have non-defined myelin loss, 
infiltration of immune cells and parenchymal edema. The immune cell influx involves 
lymphocytes and monocytes. There are studies that reveal oligodendrocyte apoptosis, but 
the degree of damage inside an active lesion can vary (Henderson et al., 2009, Greenfield 
et al., 2008). Glial scarring and regions of hypocellularity with loss of myelin characterize 
the chronic plaques. It has been noticed that histologically the lesion borders are more 
distinct and differentiated in chronic plaques. Chronic plaques can be of two distinct 
forms: chronic active lesion and chronic silent lesion. The borders of chronic active 
plaques are populated with activated microglia, macrophages and astrocytes (Greenfield 
et al., 2008). Chronic silent lesions are at a loss of inflammatory traits along the borders 
of chronic active lesions. The presence of oligodendrocyte progenitors and remyelination 
are uncommon features (Wilson et al., 2006).  
1.1.3 MS diagnosis 
Multiple sclerosis is diagnosed by using both clinical and paraclinical laboratory 
assessments (Schumacher et al., 2006, Poser et al., 1983). The diagnostic criteria’s 
emphasizes the need to demonstrate dissemination of lesions in space (DIS) and time 
(DIT). Though the diagnosis can be made on clinical grounds alone, magnetic resonance 
imaging (MRI) of the central nervous system (CNS) can be greatly supportive to 
supplement or even replace some clinical criteria, (Paty et al., 1988, Polman et al., 2005). 
This was most recently emphasized by the McDonald Criteria of the International Panel 
on the Diagnosis of MS (McDonald et al., 2001, Polman et al., 2005). 
Clinical 
presentation 
Additional data needed for MS diagnosis 
≥ 2 attacks; objective 
clinical evidence of    
≥ 2 lesions or 
objective clinical 
evidence of 1 lesion 
with reasonable 
None 
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historical evidence of 
a prior attack 
≥ 2 attacks; objective 
clinical evidence of 1 
lesion 
Dissemination in space, demonstrated by: ≥ 1 T2 lesion in 
at least 2 of 4 MS-typical regions of the CNS 
(periventricular, juxtacortical, infratentorial or spinal 
cord); or Await a further clinical attack implicating a 
different CNS site. 
1 attack; objective 
clinical evidence of ≥ 
2 lesions 
Dissemination in time, demonstrated by: Simultaneous 
presence of asymptomatic gadolinium-enhancing and 
nonenhancing lesions at any time; or A new T2 and/or 
gadolinium-enhancing lesion(s) on follow-up MRI, 
irrespective of its timing with reference to a baseline scan; 
or Await a second clinical attack. 
1 attack; objective 
clinical evidence of 1 
lesion (clinically 
isolated syndrome) 
Dissemination in space and time, demonstrated by: For 
DIS: ≥ 1 T2 lesion in at least 2 of 4 MS-typical regions of 
the CNS (periventricular, juxtacortical, infratentorial or 
spinal cord); or Await a second clinical attack implicating 
a different CNS site; and For DIT: Simultaneous presence 
of asymptomatic gadolinium-enhancing and nonenhancing 
lesions at any time; or A new T2 and/or gadolinium-
enhancing lesion(s) on follow-up MRI, irrespective of its 
timing with reference to a baseline scan; or Await a second 
clinical attack. 
Insidious 
neurological 
progression 
suggestive of MS 
(PPMS) 
1 year of disease progression (retrospectively or  
prospectively determined) plus 2 of 3 of the following 
criteria:  
1. Evidence for DIS in the brain based on ≥ 1 T2 lesions in 
the MS-characteristic (periventricular, juxtacortical or 
infratentorial) regions 
2. Evidence for DIS in the spinal cord based on ≥ 2 T2 
lesions in the cord 
3. Positive CSF (isoelectric focusing evidence of 
oligoclonal bands and/or elevated IgG index) 
Table 1: The 2010 McDonald criteria for diagnosis of MS. Revisions to MS diagnosis, (Polman et al., 2011) 
Using the McDonald Criteria results in the earlier diagnosis of MS, it helps in a highly 
specific and sensitive diagnosis, which helps in better counseling of patients and earlier 
treatment. MRI is the most sensitive test to detect and demonstrate MS lesions. It supports 
the diagnosis, estimates the lesion load and disease activity, measures brain atrophy and 
axonal loss (Milo & Miller, 2014).  
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1.1.4 Subtypes of MS  
The vast variability of the clinical course of MS raised the need for a common language 
to describe the clinical courses and pathology of multiple sclerosis. The National MS 
Society in 1996 addressed in defining four distinct clinical subtypes of MS (Hauser SL, 
2008). 
 Relapsing–remitting MS (RRMS)  
RRMS is the most common form of MS and accounts for affecting about 85% of MS 
patients. It is marked by worsening of symptoms followed by periods of remission, when 
symptoms improve or disappear. In the periods between attacks the patient has no 
worsening of neurological function. 
 Secondary progressive MS (SPMS) 
This type may develop in some patients with relapsing–remitting disease. Progressive and 
gradual neurological deterioration without acute attacks are the characteristics of disease 
course. 
 Primary progressive MS (PPMS) 
This type affects approximately 10% of MS patients. Symptoms gradually worsen from 
the beginning. The disease course is characterized by the absence of relapses or 
remissions. This form of MS is more resistant to the drugs typically used to treat the 
disease. 
 Progressive-relapsing MS 
A rare form of MS which affects fewer than 5% of patients. From the start there is steady 
functional decline, with symptoms worsening as the disease progresses. There are no 
periods of remission (Goldenberg, 2012). 
1.1.5 MS treatment 
There are no FDA-approved, curative therapies for MS currently available, although, 
various immunomodulatory agents reducing disease effects are available. These disease-
modifying agents help reducing the duration of acute exacerbations and decrease their 
frequency. The FDA has approved several medications for relapsing– remitting MS, 
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which have been shown to reduce the number of relapses and new lesions formation. Four 
beta interferons (Avonex, Betaseron, Extavia and Rebif) and one polypeptide mixture 
(Glatiramer acetate) are preferred as first-line treatments for MS. Second-line of 
therapies includes Natalizumab and Mitoxantrone (Novantrone). 
The four beta interferon drugs––Avonex (Biogen Idec), Rebif (Merck), Betaferon 
(Bayer) and Extavia (Novartis)–– are naturally occurring cytokines secreted by immune 
cells. Interferon beta-1a and beta-1b perform regulatory functions and their anti- 
inflammatory properties are beneficial (Brust, 2007). The incidence of relapses are 
reduced by beta interferons by approximately one-third (Goldenberg, 2012). 
Glatiramer acetate (Copaxone, Teva) is a synthesized copolymer polypeptide mixture 
constituting of L-glutamic acid, L-lysine, L-alanine and L-tyrosine. This drug was 
originally designed to mimic myelin basic protein (Brust, 2007). Studies have shown that 
subcutaneous injection of glatiramer acetate (20 mg/day) reduces the rate of attacks in 
patients. 
Fingolimod (Gilenya, Novartis) is the first disease-modifying drug which is administered 
orally. It reduces attacks and delays the progression of disability in patients with relapsing 
forms of MS (Brust, 2007). Fingolimod is a sphingosine-1-phosphate (S1P) receptor 
modulator. Fingolimod isolates naïve T cells, Th17 cells and central memory T cells, 
within the lymphoid tissues. These lymphocyte subsets are important for inducing the 
neurological damage in MS; their isolation in lymphoid tissues is thus expected to have 
beneficial effects in MS patients. 
Dimethyl fumarate (DMF) is a newly approved oral DMT which is taken twice-daily 
for relapsing MS. It is hydrolyzed to monomethyl fumarate on ingestion, which is 
eliminated through respiration and has little hepatic or renal excretion. Its mechanism of 
action has not been completely elucidated. Although it is known to activate the 
transcriptional pathway of nuclear-related factor 2, which reduces oxidative cell stress, 
as well as modulates nuclear factor kB, which could have anti-inflammatory effects 
(Linker et al., 2011, Albrecht et al., 2012). 
Teriflunomide is an active metabolite of the parent drug, leflunomide. Leflunomide is 
used in the treatment of rheumatoid arthritis (RA) since 1998 (Osiri et al., 2003). The 
precise mechanisms by which teriflunomide exerts its beneficial effects in MS are not 
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completely understood. Teriflunomide inhibits dihydroorotate-dehydrogenase 
(DHODH), a key mitochondrial enzyme required for rapid proliferation of cells such as 
T lymphocytes and B lymphocytes. It, therefore, diminishes the inflammatory response 
to auto-antigens.  
Alemtuzumab is a humanized monoclonal antibody directed against CD52, a 12-amino 
acid cell surface protein of unknown function (Hale, 2001, Xia et al., 1993, Xia et al., 
1991) that is expressed at high levels on T cells and B cells and at lower levels on 
monocytes, macrophages and eosinophils with small effects on natural killer cells, 
neutrophils and hematological stem cells. Cells of the innate immune system are 
unaffected. One course of intravenous treatment depletes T, B and natural killer cell 
types, especially CD4+ T cells. Although B cells repopulate within 5 to 6 months, T cells 
deplete for more than 1 year. Treatment is repeated at 1 year and may be extended 
annually thereafter.  
Daclizumab is a humanized mAb of the human IgG1 isotype that binds specifically on 
the α-subunit (CD25) of the interleukin-2 receptor (IL-2R). Due to its mitogenic effect 
on T cells it was the first interleukin molecule to be identified and characterized as ‘T-
cell growth factor’ (Smith et al., 1980). IL-2 is produced mainly by activated T cells, 
activated dendritic cells and monocytes/macrophages also produce it but to a lesser 
degree. Daclizumab, was initially designed to block virally transformed T-cell 
proliferation in human T lymphotropic virus I (HTLV-I) induced adult T-cell leukemia 
(Waldmann et al., 1985, Lehky et al., 1998). It was shown that daclizumab showed 
positive results when combined with interferon beta-1a (Wynn et al., 2010). 
Natalizumab (Tysabri, Biogen Idec/Elan) is a recombinant humanized immunoglobulin 
(IgG4) monoclonal antibody. It is administered intravenously once a month, it then works 
on reducing the attack rate (Riley CS., 2010). Natalizumab is a α4-integrin antagonist, it 
interferes with the migration of immune cells into the central nervous system. It binds to 
the α4 subunit of the α4β1-integrin and prevents leukocyte adhesion to endothelial 
vascular cell adhesion molecule-1 (VCAM-1). It thus stops the penetration of leukocytes 
into the blood brain barrier. 
Patients with relapsing–remitting MS, experience attacks with exacerbated neurological 
functioning, which is later followed with periods of partial or complete recovery 
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(remission). To relieve symptoms a combination of drugs, along with physical therapies, 
speech therapies; exercise; rest; and healthful nutrition are required (Goldenberg., 2012).
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1.2 Animal models of multiple sclerosis 
1.2.1 Overview 
About 85% of patients with MS initially have relapses. This disease phase is termed as 
relapsing-remitting MS. In about half of the patients, this is followed by secondary 
progressive MS, during which the neurological functions keep on worsening but the 
attacks have a fewer frequency (Gold et al., 2006). The single animal model of MS, 
experimental autoimmune encephalomyelitis (EAE) suggests that the disease is an 
autoimmune T-cell mediated disease. The origins of EAE date back to the 1920s, when 
Koritschoner and Schweinburg induced spinal cord inflammation in rabbits by 
inoculation with human spinal cord (Koritschoner RS., 1925). EAE since then was 
stimulated in many different species, this included rodents and primates. These studies 
made it evident that EAE could replicate and reproduce most of the clinical, 
neuropathological and immunological aspects of multiple sclerosis (Hohlfeld & 
Wekerle, 2001). Most of our current knowledge regarding principal mechanisms of 
brain inflammation has been gathered from studies on EAE and without this knowledge 
the understanding of the pathogenesis of multiple sclerosis and development of new 
therapies would not have been feasible. 
1.2.2 Experimental autoimmune encephalomyelitis (EAE) 
Experimental autoimmune encephalomyelitis (EAE) is a T cell–mediated autoimmune 
disease symbolized by CD4+ T cell and mononuclear cell inflammation. This 
subsequently leads to primary demyelination of axonal tracks in the central nervous 
system, which further results in progressive hind-limb paralysis. EAE has been shown 
to be a useful model for the study of the pathogenesis and immune regulation of CD4+ 
Th1/Th17–mediated tissue damage (Miller et al., 2007). The pathophysiology of EAE 
is based on the reaction of the immune system against brain-specific antigens. This 
reaction results in neurological and pathological features comparable to those observed 
in MS patients. These reactions involve inducing inflammation and destruction of the 
antigen carrying structures. Three different approaches for EAE can be distinguished 
as: Actively-induced EAE (aEAE; active immunization), passively transferred EAE 
(pEAE; transfer of encephalitogenic cells from an immunized animal) and more 
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recently spontaneous EAE mouse models (sEAE) which allow the study of autoimmune 
mechanisms without exogenous manipulation. aEAE however remains the easiest 
inducible model which yields fast and robust results in mice. This model is considered 
as the "gold standard" of neuroimmunological animal models by many researchers in 
the field (Stromnes & Goverman., 2006). 
For aEAE induction, the animal is immunized with a subcutaneous injection of an 
emulsion which consists of the chosen antigen and complete Freund's adjuvant (CFA) 
accompanied by an intraperitoneal injection of pertussis toxin on the day of 
immunization and two days later (booster dose). This consequently leads to the 
activation of myelin-specific T lymphocytes in the periphery and these migrate into the 
CNS across the blood-brain-barrier. Once they enter the CNS, these T-cells are 
reactivated by local and infiltrating antigen-presenting cells. This results in subsequent 
inflammatory cascades, involvement of other cells like monocytes or macrophages and 
eventually in demyelination and axonal cell death (Fletcher et al., 2010). Depending 
upon the immunization protocol, combination of mouse strain (e.g. C57BL/6, SJL/J, 
Biozzi) and the chosen antigen (e.g. myelin oligodendrocyte glycoprotein (MOG), 
myelin basic protein (MBP), myelin proteolipid protein (PLP)), the disease course can 
take an acute, chronic progressive or relapsing remitting disease course.
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Model Similarities to human disease Differences from human 
disease 
Further comments 
Lewis rat Active EAE (CNS 
myelin, MBP, MOG, PLP) 
T-cell inflammation and weak 
antibody response 
Monophasic, little demyelination Reliable model, commonly used 
for therapy studies. With guinea-
pig MBP little demyelination 
Adoptive-transfer EAE (MBP, S-
100, MOG, GFAP) 
Marked T-cell inflammation. 
Topography of lesions 
Monophasic, little demyelination Homogeneous course, rapid 
onset. Differential recruitment of 
T cells/macrophages depending 
on autoantigen 
Active EAE or AT-EAE + co-
transfer of anti-MOG antibodies 
T-cell inflammation and 
demyelination 
Only transient demyelination Basic evidence for role of 
antibodies in demyelination 
Congenic Lewis, DA, BN strains 
Active EAE (recombinant MOG 
aa 1–125) 
Relapsing–remitting disorders, 
may completely mimic 
histopathology of multiple 
sclerosis and subtypes 
No spontaneous disease Chronic disease course, affection 
of the optic nerve, also axonal 
damage similar to multiple 
sclerosis 
Murine EAE (SJL, C57BL/6, 
PL/J, Biozzi ABH) Active EAE 
(MBP, MOG, PLP and peptides) 
Relapsing–remitting (SJL, 
Biozzi) and chronic-progressive 
(C57BL/6) disease courses with 
No spontaneous disease Pertussis (toxin) required for 
many strains, whilst it is often not 
needed for SJL and some Biozzi 
EAE models. Higher variability 
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demyelination and axonal 
damage 
of disease incidence and course, 
often cytotoxic demyelination in 
C57BL/6. With rat MBP 
inflammatory vasculitis with little 
demyelination 
Murine EAE in transgenic mice 
or knockout mice (mostly 
C57BL/6 background) 
Specifically addresses role of 
defined immune 
molecules/neurotrophic 
cytokines/ neuroanatomical tracts 
Most results obtained with 
artificial permanent transgenic or 
knockouts 
Extensive backcrossing (>10 
times) on C57BL/6 background 
required. Future work with 
conditional (cre/loxP) or 
inducible (e.g. Tet-on) mutants 
Table 2: Commonly used rodent EAE models (Gold et al., 2006) 
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1.3 P38 and MK2 pathway 
Cellular behaviour responds to extracellular stimuli by mediating through intracellular 
signaling pathways such as the mitogen-activated protein (MAP) kinase pathways 
(Rouse et al., 1994). MAP kinases are members of discrete signaling cascades and serve 
as centerpieces in response to a variety of extracellular stimuli. The MAP kinase family 
has four distinct subgroups that have been described: (1) extracellular signal-regulated 
kinases (ERKs), (2) c-Jun N-terminal or stress-activated protein kinases (JNK/SAPK), 
(3) ERK/big MAP kinase 1 (BMK1) and (4) the p38 group of protein kinases.  
The p38 MAP kinase pathway is known to be rapidly tyrosine phosphorylated by heat 
shock, ultraviolet (UV) light, bacterial lipopolysaccharide (LPS) or the 
proinflammatory cytokines like IL-1 or TNF-α (Rouse et al., 1994, Freshney et al., 
1994, Han et al., 1994). Activation of the p38 pathway results in phosphorylation of 
transcription and initiation factors (Raingeaud et al., 1996, X Wang, 1998). The 
pathway also is responsible for affecting cell division, apoptosis, invasiveness of 
cultured cells and the inflammatory response (Xia et al., 1995, Takenaka et al., 1998, 
Lee, 1994, Simon et al., 1998). The functional role of the mammalian p38 MAP kinase 
cascade has been studied using mutants of the upstream regulators of the cascade, such 
as MAP kinase kinase 3/6 (MKK3/6) (Takenaka et al., 1998; Z. Xia et al., 1995) or by 
using SB203580, a specific inhibitor of the α, β-isoforms of p38 MAP kinase (Lee, 
1994; Lee et al., 1993; Simon et al., 1998; Takenaka et al., 1998). 
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Figure 4: MK2 signaling pathway (Ronkina et al., 2010) 
MAP kinase-activated protein kinase 2 (MAPKAPK2 or MK2) was the first identified 
p38α substrate (Freshney et al., 1994; Rouse et al., 1994). This substrate, along with 
MK3 its closely related family member, both activate various substrates including small 
heat shock protein 27 (HSP27) (Stokoe et al., 1992), lymphocyte-specific protein 1 
(LSP1) (Huang et al., 1997), cAMP response element-binding protein (CREB) (Tan et 
al., 1996), transcription factor ATF1, SRF and tyrosine hydroxylase (Heidenreich et al., 
1999; Thomas et al., 1997). More recently, MK2 has been found to phosphorylate 
tristetraprolin (TTP), a protein that is known to destabilize mRNA (Mahtani et al., 
2001). 
1.3.1 MK2 and Inflammation 
The central role of the p38 MAPK pathway responsible for activation of various 
downstream kinases and transcription factors limits the use of the p38 inhibitor as an 
anti-inflammatory therapy. Moreover, most of the p38 inhibitors have failed in clinical 
settings due to unacceptable safety profiles. Therefore, targeting downstream substrates 
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of p38 MAPK could be a better approach for treating various inflammatory diseases. 
MK2 is one of the several downstream substrates of p38 which has been shown to 
regulate post-transcriptional regulation of TNF-α and IFN-γ (Clark, Dean, & 
Saklatvala, 2003). MK2 acts on limited downstream substrates and therefore is a more 
specific target. Moreover, the potential side effects associated with p38 MAPK could 
be minimized by selectively targeting MK2.  
Targeted disruption of MK2 reduces TNF-α production and lipopolysaccharide (LPS)-
induced liver damage. In similarity to p38, MK2 also phosphorylates proteins that are 
found both in the nucleus (cAMP-response element binding protein (CREB)) and 
cytoplasm (HSP25/27 and LSP-1). The production of TNF-α and activation of 
inflammatory mediators that initiate leukocyte recruitment and activation are the main 
biological roles of MK2. The activation of the downstream target MK2 mainly mediates 
the inhibitory effect of p38 MAPK on TNF-α synthesis. The catalytically active MK2 
could rescue the impaired inflammatory response in MK2-deficient animals that could 
not be achieved by the catalytically inactive enzyme (Kotlyarov et al., 2002), 
suggesting its important role in release of various cytokines and chemokines. In MK2-
deficient mice, a significant reduction in NO production in response to LPS stimulation 
has been shown which provided evidence of the involvement of MK2 in NO release. 
NO on stimulation with LPS macrophages express iNOS and also participates in the 
inflammatory responses of macrophages (Lehner et al., 2002). 
1.3.2 MK2 glial cells and myelination 
Oligodendrocyte (OLG) differentiation and myelination is affected by p38 mitogen-
activated protein kinase (MAPK) (Fragoso et al., 2007; Haines et al., 2008). When 
oligodendrocyte progenitors are treated with p38 inhibitors, their differentiation and 
myelination of dorsal root ganglion neurons is reduced. When p38 was silenced using 
siRNA, it decreases staining levels of myelin-associated glycoprotein (MAG) and 
galactosyl-ceramide (GaIC) in OLG membrane sheets (Fragoso et al., 2007). It is easy 
to conclude from these results that p38 is essential for OLG differentiation. 
There are a number of kinases through which p38 MAPK signals, including MK2 which 
is the most studied kinase (Gaestel, 2006; Ronkina et al., 2008). p38 MAPK 
phosphorylates MK2 on multiple amino acid residues, which result in its activation 
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(Ben-Levy et al., 1995). In early stages of OLG development, levels of phosphorylated 
MK2 were high but the levels decrease slightly with differentiation. MK2 is involved 
in OLG lineage progression since a pharmacological inhibitor (CMPD1) and siRNA to 
MK2 decreased myelin-lipids and proteins while increasing several factors that prevent 
differentiation. CMPD1 decreased several myelin-specific proteins, like MAG and 
MBP (Gaestel., 2006). Treatment of OPCs with MK2 inhibitor CMPD1 decreased 
myelin proteins in OLG membrane sheets. MK2 siRNA decreased MAG expression. 
The mRNA levels of myelin-specific markers were reduced after using CMPD1 while 
increasing the factors, which inhibit OLG differentiation. This implicates the role of 
MK2 in the regulation of OLG differentiation at the transcriptional level.  
It was observed that pMK2 levels were increased in early-stage OLGs, which suggested 
a role for activated MK2 in OLG differentiation, which could affect cell cycle control, 
migration and cytoskeletal remodeling as reported in other systems (Ronkina et al., 
2008).  
The effect of the inhibitor was more pronounced when applied at the OPC stage, which 
helps concluding that MK2 activity is important for early stages of differentiation. The 
levels of transcription factor Myt1, which is involved in OLG lineage progression, had 
the most dramatic effects of CMPD1 inhibition (Nielsen et al., 2004). The reduction in 
Myt1 levels by almost 90% suggested that MK2 is involved in an early stage in 
progression of OPCs to a differentiated state. Furthermore, we found that MK2 
signaling regulated mRNA levels of various transcriptional repressors in 
oligodendrocytes. 
Similar to what has been observed with p38 staining, pMK2 was found to be diffusely 
distributed in cytoplasm and nucleus of OPCs, but became more intensely localized to 
the nucleus as the cells matured (Haines et al., 2008). Activated MK2 can influence p38 
compartmentalization through regulation of a MK2 nuclear export signal (Engel, 
Kotlyarov & Gaestel, 1998; Kotlyarov et al., 2002). Depending on their subcellular 
localization during differentiation, MK2 and p38 may play different roles in 
oligodendrocytes. Studies done by Haines et al., (2010) found that p38 and MK2 form 
co-immunoprecipitable complexes in OPCs. 
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1.3.3 MK2 and EAE 
The role of the MK2 has been investigated in various disease models before. All studies 
which had used MK2-/- mice, the knockout proved to be more beneficial and mice 
showed reduced disease symptoms in e.g. spinal cord injury, Parkinson’s disease and 
cerebral ischemia (Ghasemlou et al., 2010; Gorska et al., 2007; T. Thomas, Timmer, et 
al., 2008; Xinkang Wang et al., 2002). The role of p38 the upstream kinase of MK2 has 
been previously examined in EAE. The development and progression of both chronic 
and relapsing-remitting EAE has been shown to require the activation of p38 and its 
inhibition reduces the disease signs. To be precise, the disease severity is modulated by 
the p38 activity by regulating T cells activity (Noubade et al., 2011). In addition, it was 
found that inhibition of the p38 reduces the pathogenesis of EAE by decreasing the IL-
17 production (Namiki et al., 2012). 
As opposed to that, Tietz et al., (2014) found that a lack of the downstream kinase MK2 
was not an advantage in MOG35-55-induced EAE. In this study it was shown that 
elimination of MK2 in mice is beneficial in EAE, although pro-inflammatory cytokines 
were reduced. During the course of EAE, TNF-α was not detectable in the serum of 
MK2-/- mice, implying that MK2-/- mice may resemble the disease course of TNF-α 
knockout mice. The onset of MOG35-55-induced EAE was not affected by MK2 
knockout as in the case of TNF-α-deficiency, but led to prolonged disease activity 
correlating with more mononuclear cells infiltrated into the CNS (Liu et al., 1998; 
Probert et al., 2000). 
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Figure 5: MK2 deficiency leads to severity and prolongation of EAE (Tietz et al., 2014) 
In summary, the previous study done in our lab underlines the significance of MK2 in 
the regulation of CNS inflammatory disease, multiple sclerosis and its animal model, 
EAE. The initial hypothesis was rejected in the study as MK2 deficiency resulted in a 
more severe disease course and was associated with more cellular CNS inflammation. 
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2 Objectives 
The p38/MK2 pathway is known to regulate inflammatory reactions and pathological 
processes. The pathway controls many downstream transcription factors that regulate 
many cellular functions. Therefore, we hypothesized that the deletion of MK2 in 
C57BL/6J mice would lead to a mild course of EAE accompanied by low inflammation 
and neurodegeneration. 
The aim of this study was to characterize the role of MK2 in experimental autoimmune 
encephalomyelitis, the most common animal model of multiple sclerosis. 
1. To investigate the role of MK2 in disease severity in acute and chronic 
experimental autoimmune encephalomyelitis.  
2. To characterize the morphology, histology and distribution of immune cells in 
spinal cord lesions of MOG35-55-EAE. 
3. To study the expression and regulation patterns of the MK2 knockout 
downstream signalling pathway in MK2-/- mice. 
4. To study the pharmacological effects of GA in MK2-/- C17.2 cells. 
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3 Materials and Methods 
3.1 MATERIALS 
3.1.1 Animals 
3.1.1.1 Mice provider 
Mice line Supplier Animal facility 
MK2/MK3-/+ MH Hannover JLU, Central Animal facility, 
Frankfurter strasse, Giessen, Germany. 
C57BL/6J   
3.1.1.2 Mice Diet 
Diet Name Provider 
Trauben zucker Müller’s Mühle Gmbh, Gelsenkirchen, Germany 
DietGel Boost ClearH2O®  Westbrook, ME 
DietGel Recovery ClearH2O®  Westbrook, ME 
3.1.2 Cell lines 
Cell Line Provider 
C17.2 Neurologie Klinikum, MS Research group, Gießen 
JURKAT Neurologie Klinikum, MS Research group, Gießen 
3.1.3 Primary antibodies 
Name Host Reactivity 
Mol. 
Weight 
Method 
Article 
Nr 
Manufacturer 
Anti-pStat1 Rabbit H, M, R 
84/91 
kDa 
WB 9171s 
Cell Signaling 
Tech, MA, 
USA 
Anti-Stat1 Rabbit 
H, M, R, 
MK 
84/91 
kDa 
WB 9172 
Cell Signaling 
Tech, MA, 
USA 
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Anti-CNPase Mouse H, M, R 
46/48 
kDa 
WB ab6319 Abcam, UK 
Anti-MBP Mouse H, M, R, G 33 kDa WB ab62631 Abcam, UK 
Anti-PLP Rabbit H, M 
26/30 
kDa 
WB ab28486 Abcam, UK 
Anti-pERK p-44/42 Rabbit 
H M R Hm 
Mk 
44, 42 WB 4370s 
Cell Signaling 
Tech, MA, 
USA 
Anti-Erk 1/2 Rabbit 
H, M, R, 
MK 
42/44 
kDa 
WB 9102 
Cell Signaling 
Tech, MA, 
USA 
Anti-Akt Rabbit 
H, M, R, 
MK 
60 kDa WB 9272 
Cell Signaling 
Tech, MA, 
USA 
Anti-pAkt (Ser473) Rabbit 
H, M, R, 
MK 
60 kDa WB 4060s 
Cell Signaling 
Tech, MA, 
USA 
Anti-GAPDH Mouse Ca, H, M, R 38 kDa WB MAB374 
Chemicon/ 
Millipore, CA; 
USA 
Anti-Trk B (794):sc12 Rabbit H, M, R 145 kDa WB sc-12 
Santa Cruz 
Biotech, CA, 
USA 
Anti-BDNF Rabbit H, M, R 
17, 13 
kD 
WB sc-546 
Santa Cruz 
Biotech, CA, 
USA 
Mac 3 Clone M3/84 Rat M staining IHC 553322 
Pharmingen, 
USA 
B220 clone RA3-6B2 Rat H, M staining IHC 557390 
Pharmingen, 
USA 
CD3, clone CD3-12 Rat M staining IHC 
MCA 
1477 
Serotec, UK 
25 
 
MBP Rabbit M, R staining IHC 62301 Dako, Germany 
MAPKAPK2 Rabbit 
H, M, R, 
Mk 
47, 49 
kDa 
WB 3042 
Cell Signaling 
Tech, MA, 
USA 
pMAPKAPK2(Thr334) Rabbit 
H, M, R, 
Mk 
49kDa WB 3007 
Cell Signaling 
Tech, MA, 
USA 
P38 MAPK Rabbit 
H, M, R, 
Mk 
43 kDa WB 9212 
Cell Signaling 
Tech, MA, 
USA 
Phospho-p38 MAPK Rabbit 
H, M, R, 
Mk 
43 kDa WB 9211 
Cell Signaling 
Tech, MA, 
USA 
NF-kB p65 Rabbit 
H, M, R, 
Mk 
65 kDa WB 4764 
Cell Signaling 
Tech, MA, 
USA 
Phospho-NF-kB p65 Rabbit 
H, M, R, 
Mk, Hm 
65 kDa WB 3033 
Cell Signaling 
Tech, MA, 
USA 
IkBα Rabbit 
H, M, R, 
Mk, Hm 
39 kDa WB 4812 
Cell Signaling 
Tech, MA, 
USA 
Phospho-IkBα (ser32) Rabbit 
H, M, R, 
Mk 
40 kDa WB 2859 
Cell Signaling 
Tech, MA, 
USA 
3.1.4 Secondary antibodies 
Antibody Host Article Nr Manufacturer 
Anti-Rabbit-HRP Goat sc-2004 Santa Cruz Biotech, CA, USA 
Anti-Mouse-HRP Donkey sc-2318 Santa Cruz Biotech, CA, USA 
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3.1.5 Kits 
Kit Manufacturer Article Nr Method 
BCA Protein Assay Kit  
 
Pierce® Thermo 
Scientific, IL, USA 
23225 
Protein 
quantification 
Cell Proliferation reagent 
WST-1 
Roche Applied Science, 
Mannheim, Germany 
11644807001 
Proliferation 
assay 
DirectPCR Lysis Reagent 
(Tail) 
Peqlab, Erlangen, 
Germany 
31-121-T DNA isolation 
iTaqTM Universal 
SYBR® Green qPCR 
Master Mix  
Bio-Rad, CA, USA 172-5124 PCR 
QuantiTect® Reverse 
Transcription Kit 
Qiagen GmbH, Hilden, 
Germany 
205310 
Reverse 
Transcription 
SuperSignal® West Pico 
Chemiluminescent 
substrate 
Thermo Scientific, Il, 
USA 
34077 Western Blot 
Viromer® BLUE 
 
Lipocalyx GmbH, Halle, 
Germany 
 Transfection 
Lipofectamine® 
RNAiMAX Transfection 
Reagent  
 
Thermo Scientific, Il, 
USA 
13778075 Transfection 
HotStarTaq DNA 
Polymerase (250 U) 
Qiagen GmbH, Hilden, 
Germany 
203203 PCR 
3.1.6 Genotyping Primers 
Primers were designed using NCBI primer designing tool and all primers were 
purchased from Eurofins Genomics, Ebersberg, Germany. 
Gene (Primer) Primer name Sequence 
MK2 MK2-/- Tneorc CTGTTGTGCCCAGTCATAGCCG 
 MK2+/+ MK2 200rc CCCTCTCTACCTCTTTCTGTGAATGCC 
27 
 
 MK2+/+ TMK2 dl CATGCCATGATGAGGTGCCTCTGC 
MK3 MK3 WT Forward GCCAATGTCCCGCATTATCTCTGC 
 MK3 WT Reverse CAGGGAGCACTCACAGAGCAGTGGGC 
3.1.7 Primers used for analysis 
Primer 5’               3’   Sequence 
TNF-α  
Forward   
CGGTCCCCAAAGGGATGAGAAGT 
Reverse   ACGACGTGGGCTACAGGCTT 
IL-1β 
Forward  TACCTGTGGCCTTGGGCCTCAA 
Reverse  
GCTTGGGATCCACACTCTCCAGCT 
IL-6 
Forward  CTCTGCAAGAGACTTCCA 
Reverse  AGTCTCCTCTCCGGACTT 
IL-12 
Forward  AGACCACAGATGACATGGTGA 
Reverse  ACGACGTGGGCTACAGGCTT 
iNOS 
Forward  TTGGAGGCCTTGTGTCAGCCCT 
Reverse  AAGGCAGCGGGCACATGCAA 
BDNF 
Forward  AAGGGCCAGGTCTGTTAAGC 
Reverse  GGTAAGAGAGCCAGCCACTG 
TrkB 
Forward  TGACGCAGTCGCAGATGCTG 
Reverse  TTTCCTGTACATGATGCTCTCTGG 
GAPDH 
Forward  GGATGGGTCCTCATGCTCAC 
Reverse  TGGTGCTGCAAGTCAGAGCAG 
TGF-β 
Forward  CTCCTGCTGCTTTCTCCCTC 
Reverse  GTGGGGTCTCCCAAGGAAAG 
SEMA3A 
Forward  GGATGGGTCCTCATGCTCAC 
Reverse  TGGTGCTGCAAGTCAGAGCAG 
Lingo1 
Forward  TCATCAGGTGAGCGAGAGGA 
Reverse  CAGTACCAGCAGGAGGATGG 
PLP Forward GAGCAAAGTCAGCCGCAAAA 
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Reverse CAAGCCCATGTCTTTGGCAC 
MBP 
Forward TCCATCGGGCGCTTCTTTAG 
Reverse TCTCGTGTGTGAGTCCTTGC 
3.1.8 Ladders 
Marker Manufacturer 
PageRulerTM Plus Prestained Protein 
Ladder 
Fermentas, Invitrogen, Carlsbad, USA 
Fluorescent Low Range DNA Ladder Jena Bioscience, Jena, Germany 
Mid Range DNA Ladder Jena Bioscience, Jena, Germany 
3.1.9 Chemicals 
Compound Manufacturer 
10x PBS for cell culture (DPBS) Lonza, Köln, Germany 
2-Mercaptoethanol Sigma-Aldrich, Steinheim, Germany  
2-Propanol Sigma-Aldrich, Steinheim, Germany 
3% Hydrogen peroxide Carl Roth, Karlsruhe, Germany 
Acetic acid Merck, Darmstadt, Germany 
Agarose Bioline GmbH, Luckenwalde, Germany 
Ammonium Persulphate (APS) Carl Roth, Karlsruhe, Germany 
Bovine Serum Albumin (BSA) Merck, Darmstadt, Germany 
Bromophenol Blue Neolab, Heidelberg, Germany 
Citric acid Merck, Darmstadt, Germany 
Complete Freund´s adjuvant Sigma, Steinheim, Germany 
Distilled water (Ecostrain®) Braun, Melsungen, Germany 
Dimethylsulfoxide (DMSO) Carl Roth, Karlsruhe, Germany 
Disodium-hydrogen-phosphate  Merck, Darmstadt, Germany 
DNase Qiagen, Hilden, Germany 
EDTA Carl Roth, Karlsruhe, Germany 
Eosin Merck, Darmstadt, Germany 
Eosin Carl Roth, Karlsruhe, Germany 
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Ethanol 100% Sigma-Aldrich, Steinheim, Germany 
FBS PAA Laboratories, Pasching, Austria 
Glycerol Carl Roth, Karlsruhe, Germany 
Glycine Merck, Darmstadt, Germany 
Glycerin Carl Roth, Karlsruhe, Germany 
Hematoxylin Carl Roth, Karlsruhe, Germany 
Isopropanol Merck, Darmstadt, Germany 
Ketamine Inersa Arzneimittel GmbH, Freiberg, 
Germany 
Luxol-Fast-Blue Sigma-Aldrich, Steinheim, Germany 
Magnesiumsulfate (MgSO4) Sigma Aldrich, Tachfkirchen, Germany 
Methanol Merck, Darmstadt, Germany 
MOG35-55 Charité Berlin, Berlin, Germany 
Mycobacterium tuberculosis Difco Microbiology, Michigan, USA 
NP40 US Biologicals, MA, Germany 
Paraformaldehyde (PFA) Sigma Aldrich, Taufkirchen, Germany 
Pertussis Toxin Calbiochem, Darmstadt, Germany 
Poly-L-Lysine Sigma-Aldrich, Steinheim, Germany 
Potassium chloride (KCL) Merck, Darmstadt, Germany 
Potassiumdihydrogenphosphate  Merck, Darmstadt, Germany 
Protease Inhibitor cocktail Roche, Manheim, Germany 
Proteinase K Sigma-Aldrich, Missouri, USA 
RNAse free water Millipore corporation, MA, USA 
Rotiphorese Gel (30% acrylamide mix) Carl Roth, Karlsruhe, Germany 
Sodium chloride (NaCl) Carl Roth, Karlsruhe, Germany 
Sodium-dihydrogen-phosphate  Merck, Darmstadt, Germany 
Sodium hydrogen carbonate (NaHCO3) Merck, Darmstadt, Germany 
Sodiumdodecylsulfate (SDS) Neolab, Heidelberg, Germany 
Sodiumazid (NaN3) Merck, Darmstadt, Germany 
Sunflower oil Sigma-Aldrich, Steinheim, Germany 
Tamoxifen Sigma-Aldrich, Steinheim, Germany 
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TEMED Carl Roth, Karlsruhe, Germany 
Tris HCl Carl Roth, Karlsruhe, Germany 
Tris. acetat-EDTA buffer (TAE) 10x Carl Roth, Karlsruhe, Germany 
Trishdroxymethyl aminomethan (Tris) Carl Roth, Karlsruhe, Germany 
Tryphanblue Carl Roth, Karlsruhe, Germany 
Trypsin (2.5g/l) Gibco, Invitrogen, Carlsbad, USA 
Tween 20 Merck, Darmstadt, Germany 
Xylazin 2% CEVA Tiergesunheit GmbH, Düsseldorf, 
Germany 
3.1.10 Laboratory consumables 
Consumables Manufacturer 
Cellstar® 6 Well and 24 well Cell Culture 
Plate 
GreinerBioOne, Frickenhausen, Germany 
Cellstar® Plastikpipettes (5 ml, 10 ml) GreinerBioOne, Frickenhausen, Germany 
Cellstar® U-shape with Lid, TC-Plate, 96 
well, sterile 
GreinerBioOne, Frickenhausen, Germany 
Cellstar® Flat bottom with Lid, TC-Plate, 
96 well, sterile 
GreinerBioOne, Frickenhausen, Germany 
Cellstar® 75 cm2 Cell cultur flasks GreinerBioOne, Frickenhausen, Germany 
Cellstar® 125 cm2 Cell cultur flasks GreinerBioOne, Frickenhausen, Germany 
Cell scrapper GreinerBioOne, Frickenhausen, Germany 
Cryobox 136x136x130 mm Ratiolab GmbH, Dreieich, Germany 
Cryo TubeTM vials (1,8 mL; 4,5 mL) Sarstedt AG & Co, Nümbrecht, Germany 
Falcon tubes (15ml, 50ml) Becton Dickinson, Heidelberg, Germany 
Glass Pasteur pipettes 150 mm Brand, Wertheim, Germany 
Ministart single use filter (0,2 μm, 0,45 μm) Sartorius Stedim Biotech GmbH, Göttingen, 
Germany 
Nitra-Tex® powder free gloves B. Braun Melsungen AG, Germany 
Parafilm Pechiney Plastic packaging, Menasha, WI 
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Pipette tips without filter (10 μL, 100 μL, 
1000 μL) 
Sarstedt AG & Co, Nümbrecht, Germany 
Eppendorf tubes 1,5 mL, 2mL Eppendorf Vertrieb Deutschland GmbH, 
Wesseling-Berzdorf, Germany 
Eppendorf tubes 1,5 mL, 2mL (PCR clean- 
pyrogen & DNase free) 
Nerbe Plus GmbH, Winsen (Luhe), Germany 
Sterile PCR- clean pyrogen & DNase free 
with filter (10, 100, 200, 1000µl) 
Nerbe Plus GmbH, Winsen (Luhe), Germany 
Tissue culture dishes steril 35,0 /10mm GreinerBioOne, Frickenhausen, Germany 
UV-Spectroscopic cuvettes (RNA 
quantification) 
BioRad, München, Germany 
Falcon® Plastic pipettes 10ml, 5ml Becton Dickinson, Heidelberg, Germany 
Glasswares (different sorts) Fisherbrand; IDL; Schott&Gen; Simax 
Syringe 25ml for BSA  B. Braun Melsungen AG, Germany 
Nitrocellulose membrane GE Healthcare, AmershamTM Hybond ECL, 
Buckinghamshire, UK 
PCR Tube, cap-strips Applied Biosystems, Darmstadt, Germany 
3.1.11 Laboratory instruments 
 
Instrument Manufacturer 
Arpege 75, Liquid nitrogen tank  
Air Liquide Medical GmbH, Düsseldorf, 
Germany  
Axioplan 2 Fluorescence Microscope Carl Zeiss, Jena, Germany 
BEP 2000 Advance (ELISA-Reader)  
Dade Behring Marburg GmbH, Marburg, 
Germany 
Centrifuge type 2-6 Easia shaker 
Medgenix diagnostics 
Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Centrifuge Universal 32 R  Hettich GmbH, Kirchlengen, Germany 
ELISA-Reader Multiscan EX 
Thermo electron corporation, Langenselbold, 
Germany 
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Fusion FX7 chemiluminescence system 
Peqlab Biotechnologie GmbH, Erlangen, 
Germany  
Hettich centrifuge (cooling) Hettich GmbH, Kirchlengen, Germany 
Light Microscope for cell culture 
Carl Zeiss Microscopy GmbH, Oberkochen 
Germany 
Magnetic stirrer IKA Werke GmbH, Staufen, Germany 
Nalgene Cryo 1°C Freezing container  Nalgene®, Germany 
Nanophotometer Implen GmbH, München, Germany 
Neubauer improved cell chamber Brand, Wertheim, Germany 
Neubauer improved Haemocytometer Brand, Wertheim, Germany 
Nuaire Biological Safety Cabinets Class 
II type A/B3 (Sterilbank) 
INTEGRA Biosciences GmbH, Fernwald, 
Germany 
pH-Meter Mettler Toledo GmbH, Giessen, Germany 
Pipette boy 
INTEGRA Biosciences GmbH, Fernwald, 
Germany 
Power pack 
Peqlab Biotechnologie GmbH, Erlangen, 
Germany  
Refrigerators and freezers Different companies 
Rotamax 120 (Shaker) 
Heidolph Instruments GmbH & Co. KG,   
Schwabach, Germany  
Sanyo Incu-safe incubator for cell culture 
Ewald Innovationstechnik GmbH, Bad 
Nenndorf, Germany 
SmartSpecTM Plus Spectrophotometer BioRad, München, Germany 
StepOne® Real-Time PCR system  Applied Biosystems, Darmstadt, Germany 
Surgical instruments Various companies 
Table top centrifuge EBA 20 Hettich GmbH, Kirchlengen, Germany 
Table top centrifuge micro 120 Hettich GmbH, Kirchlengen, Germany 
TissueRuptor 
Qiagen Instruments, Hombrechtikon, 
Switzerland 
Trans-Blot® SD Semi-dry transfer cell BIO RAD, München, Germany  
Trans-Blot® SD Semi-dry transfer cell BioRad, München, Germany 
Western blotting system BioRad, München, Germany 
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3.1.12 Buffers 
Buffer Components Volume 
1X SDS-PAGE Running Buffer Rotiphorese® 10X 
Running Buffer 
H2O 
 
100 ml 
900 ml 
10x PBS (1 Liter) 
pH 7.4 
137 mM NaCl   
2 mM KH2PO4 
2.7 mM KCl  
10 mM Na2HPO4  
H2O 
80 g 
2.4 g 
2 g 
14.4 g 
1000 ml 
10x TBS (1 Liter) 
pH 7.2 to 7.6 
Tris   
NaCl  
H2O 
24.2 g 
87.7 g 
1000 ml 
1x TBS-Tween (TBST)  
(1 Liter) 
1x TBS  
0.1% Tween®20   
1000 ml 
1 ml 
Lysis Buffer (250ml) 
pH 7.4 
NaCl   
Tris  
EDTA  
Glycerol   
NP40  
NaN3 
2.19 g 
0.61 g 
0.07 g 
25 ml 
2.5 ml 
0.025 g 
6x SDS-PAGE Loading Buffer  60 mM Tris-HCl (pH 6.8) 
2% SDS  
0.01% Bromophenol blue  
10% Glycerol  
ddH2O  
36 ml 
60 ml 
60 mg 
60 ml 
144 ml 
Vortexer vortex-Genie2 
Heidolph Instruments GmbH & Co. KG,   
Schwabach, Germany  
Water bath Memmert GmbH + Co.KG, Germany 
Weighing balance 
Sartorius Stedim Biotech GmbH, Göttingen, 
Germany 
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β-Mercaptoethanol 65 µl/ml  
SDS-PAGE Transfer buffer  
(1 Liter) 
10x Running buffer  
Methanol  
ddH2O 
100 ml 
200 ml 
700 ml 
Blocking buffer (5% BSA)  
Bovine Serum Albumin 
BSA fraction V  
TBST 
5 g 
100 ml 
10x Trypsin EDTA 10x Trypsin 
ddH2O 
5 ml 
45 ml 
10% Ammonium Persulfate (APS) APS 
ddH2O 
1 g 
10 ml 
10% Sodiumdodecylsulfate (SDS) SDS 
ddH2O 
1 g 
10 ml 
3.1.13 Softwares 
Fusion Bio1D software (Peqlab, Erlangen, Germany) 
Microsoft Office Professional Plus 2010 (Microsoft corporation, USA) 
Image J software (Image J 1.47d, National Institute of Health, USA) 
StepOne RealTime PCR Software v2.1 (Applied Biosystems, Darmstadt, Germany) 
GraphPad Prism Software Version 7.01 (GraphPad Software, Inc. CA, USA). 
3.2 Methods 
3.2.1 Mice 
C57BL/6J OlaHsd, MAPKAPK2+/- and MAPKAPK3+/- (MK2/MK3+/-) mice were 
supplied from the MH Hannover (AG Prof. Dr. Gästel). These mice were crossed to 
yield the mice MAPKAPK2-/- (known as MK2-/-). Mice were bread and grown in JLU-
central animal facility, Frankfurter Strasse 110, Giessen, Germany. All animal 
experiments were carried out in JLU central animal facility and analyzed in the 
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Neurochemisches Labor, Department of Neurology, Giessen, Germany. Animal studies 
were performed according to the guidelines of FELASA and local authority of animal 
ethical committee. Animal experiments were approved by the local state authorities of 
Hessen, Giessen, Germany (GI 20/23-Nr. 31/2008) and Institutional Animal Care and 
Use Committee at Justus Liebig University. All efforts were made to minimize pain 
and suffering. 
3.2.1.1 Preparation of mice genomic DNA 
The genotype was controlled by PCR (DirectPCR-Tail, Peqlab, Erlangen, Germany) 
using MK2 Wild type, MK2 Knockout and MK3 Wild type locus. Presence of MK2 
gene was confirmed using PCR with SYBR green and then running the agarose gel to 
identify the bands. The second PCR was done to control MK3 WT gene using HotStar 
Taq polymerase QIAGEN and running another agarose gel with DNA binding dye to 
identify the bands. 1mm portion of the tail from each mice were lysed to obtain DNA 
lysates in 200µl of Direct PCR tail reagent with 0.3mg/ml proteinase K for overnight 
at 55 °C to digest the tissues and then for 45 minutes at 85 °C to deactivate Proteinase 
K. The tail lysates were centrifuged for 20 seconds to settle down the debris. 1 µl of 
this tail lysate which contain the genomic DNA was used for genotyping PCR.  
3.2.1.2 Genotyping and identification of locus  
Genomic DNA from all mice (1 µl) was used in SYBR Green PCR and HotStar Taq 
Polymerase QIAGEN; the primers for MK2 and MK3 locus were used.  
MK2 master mix per probe  10 µl SYBR Green master mix  
6 µl H2O 
1 µl TMK2 dl 
1 µl Tneorc  
1 µl MK2 200rc 
1 µl genomic DNA 
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3.2.1.3 Band detection in the agarose gel for MK2 PCR 
For the MK2 PCR both WT and Knockout bands were detected in the same gel as 
opposed to the MK3 gel which is explained later. 3 different primers were used; TMK2 
dl and MK2 200rc detected the WT bands (200bp), TMK2 dl and Tneorc detected the 
KO bands (560bp). Amplified PCR product was run in 1.5% agarose gel electrophoresis 
at 120v for 45 min (BioRad electrophoresis) and bands were identified using Fusion 
Fx7 chemiluminescence system (PEQLAB, Erlangen, Germany). 
MK3 master mix probe: 10 µl SYBR Green master mix  
6 µl H2O 
1 µl MK3 WT Fw 
1 µl MK3 WT Rev 
1 µl genomic DNA  
 
MK3 KO master mix per probe 2.5 µl PCR Buffer 10X (pH=8.7) 
1 µl Q-solution 5X 
0.2µl Hot Star-Taq-Polymerase5 U/µL 
14.8 µl H2O 
1 µl MK3 WT Fw 
1 µl MK2 Tneorc 
0.5 µl dNTP 10.0 mM 
0.5 µl MgCl 25 mM 
1 µl genomic DNA 
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3.2.1.4 Band detection in the agarose gel for MK3 PCR 
There are two separate PCR reactions for detection of MK3 wild type and knockout 
alleles. In one of the PCR reactions two primers were used (MK3 WT FwP, MK3 WT 
RevP) which detected the WT bands (879). Amplified PCR product was run in 1.5% 
agarose gel electrophoresis at 120v for 45 min (BioRad electrophoresis) and bands were 
identified using Fusion Fx7 chemiluminescence system (PEQLAB, Erlangen, 
Germany). For the detection of the MK3 knockout bands (1239bp) the PCR reaction 
was done using the QIAGEN HotStar TAQ DNA polymerase (reaction mixture 
specified above). So, for the detection of bands in the gel we use a DNA dye 
(GelGreen™ Nucleic Acid Gel Stain, Biotium, Hayward, CA) 8µl for 100ml of agarose 
gel. Amplified PCR product was run in 1.5% agarose gel with 8µl of DNA dye; 
electrophoresis at 120v for 50 min (BioRad electrophoresis) and bands were identified 
using Fusion Fx7 chemiluminescence system (PEQLAB, Erlangen, Germany). 
3.2.1.5 PCR thermal profile for genotyping 
MK2 Locus: 
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MK3 Locus: 
There are separate PCR reactions for detection for MK3 wild type and knock out alleles.  
MK3 WT PCR 
 
MK3 KO PCR 
 
3.2.1.6 Anesthesia in mice 
All animals were anesthetized with isoflurane prior to treatment. For this purpose, a 
paper towel was impregnated with 5% isoflurane and placed in a glass container with a 
perforated metal bottom. While injecting the mice with MOG-emulsion for EAE 
induction, 1.5-2% of isoflurane was given with the help of an anesthesia machine. 
3.2.1.7 Induction of MOG35-55-induced EAE and clinical scoring  
Mice were anesthesized using isoflurane as explained above and then EAE was 
induced. EAE induction was done in 10-12 weeks old female C57BL/6JOlaHsd and B6 
Mapkapk2 tm1Mg1. On day 0 both WT and MK2-/- mice were injected intraperitonialy 
with 300ng of pertussis toxin in 100 μl PBS (Cannula size: 0.4 x 12 mm; Gr. 27). 
Subcutaneous injection of 300 µg myelin oligodendrocyte glycoprotein peptide 
(MOG35-55; MEVGWYRSPFSRVVHLYRNGK; Charité Hospital, Berlin, Germany) 
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emulsified in complete Freund´s adjuvant (Sigma, Steinheim, Germany) containing 10 
mg/ml Mycobacterium tuberculosis (Difco, Michigan, USA) were injected in 2 upper 
flanks and 2 lower flanks (Cannula size: 0.55 x 25 mm;. Gr 17). 48 hrs later (day 2) a 
booster dose of pertussis toxin was given intraperitonialy as described above.  
 
Figure 6: Induction of MOG35-55-induced EAE 
3.2.1.8 Determining the extent of EAE: 
The immunized animals are observed for clinical signs daily until the end of the 
experiment. Mice were euthanized on day 16 p.i. (acute phase) and day 60 p.i. (chronic 
phase) for analysis. The extent of the neurological symptoms is quantified according to 
the following scale: 
0 no discernible signs 
0.5 partial tail paralysis 
1 complete tail paralysis 
1.5 slight hind limb paralysis 
2 moderate hind leg paralysis 
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2.5 severe hind limb paralysis 
3 Complete hind limb paralysis 
3.5 Complete hind limb paralysis and paralysis of the front legs 
3.2.1.9 Score sheet:  
The following score sheet was maintained in the animal facility according to the local 
authority recommendation to minimize the pain and suffering in mice. All the factors 
were checked, which control the wellbeing of animals. These include body weight, 
bladder functions, observing the grooming of mice etc. There were decided scores given 
for everything. Mice were euthanized and removed from the experiment when they 
reaches the score of 45 with clinical score alone or with these factors combined. 
1. Körpergewicht  
Bezogen auf Ausgangsgewicht [  x]  
Bezogen auf Gewicht der Kontrollgruppe [  ] 
Score 
Unbeeinflusst oder Anstieg 0 
Reduktion > 20% 10 
Reduktion > 25% 20 
2. Allgemeinzustand  
Fell glatt, glänzend und anliegend, Augen glänzend, 
Körperöffnungen sauber 
0 
Fell matt, Augen trüb 5 
Fell stumpf, Augen eingesunken trüb, verklebte oder 
feuchte Körperöffnungen 
10 
Fell gesträubt, Tier fühlt sich kalt an, Augen geschlossen, 
Krämpfe, Atemgeräusche, bläuliche Schleimhäute 
20 
3. Spontanverhalten  
aufmerksam, neugierig, Aufrichten, flinke Bewegungen 0 
ungewöhliches Verhalten, eingeschränkte oder reduzierte 
Bewegung oder Überaktivität, reduziertes 
Explorationsverhalten 
5 
Isolation, Apathie, ausgeprägte Sterotypiene oder 
Hyperkinetik 
10 
Automutilation, Rektumvorfall 20 
4. Versuchsspezifische Kriterien  
EAE Score 1 (Schwanzlähmung) 0 
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EAE Score 2 (Hinterlaufparese) 5 
EAE Score 3 (Hinterlaufplegie) 10 
EAE Score 3,5 (Hinterlaufplegie und Vorderlaufschwäche) ohne 
relevante Einschränkung der Mobilität  
15 
EAE Score 3,5 (Hinterlaufplegie und Vorderlaufschwäche) mit 
relevanter Einschränkung der Mobilität 
20 
  
Nekrose/Ulzeration an einer der 4 Injektionsstellen (CFA-
Application) 
5 
Nekrose/Ulzeration an 2-3 Injektionsstellen (CFA-Application) 10 
Nekrose/Ulzeration an 4 Injektionsstellen (CFA-Application) 20 
Bewertung und Maßnahme  
Keine Belastung  
Geringgradige Belastung: 1 xtgl beobachten, bei 
Nekrose/Ulzeration an der Injektionsstelle (CFA-Applikation), mit 
Bepanthensalbe und ggf. antibiotische Salben behandeln. Wenn 
nach 3 Tagen kein Einsetzen der Wundheilung oder Verstärkung 
der Entzündungsreaktion, dann Abbruch. 
Bis 9 
Mittelgradige Belastung: 2 xtgl beobachten,  
Wasserflaschen mit langen Trinkhälsen (7 cm), Futterstelle auf dem 
Käfigboden und  Ernährung mit DietGel Recovery, 15% Glucose 
neben normalem Trinkwasser anbieten, „Paper shavings“ 
(Cellulose) zur verbesserten Flüssigkeitsresorption und 
Verhinderung des sich Wundreibens, Versuchsleiter und 
Tierarzt  informieren, Heating plate längerandauernd als 1 Woche 
gilt als hochgradige Belastung 
Bei Nekrosen: Wenn nach 3 Tagen kein Einsetzen der Wundheilung 
oder Verstärkung der Entzündungsreaktion, dann Abbruch. 
10 - 19 
Hochgradige Belastung: 2 x tgl beobachten, Versuchsleiter und 
Tierschutzbeauftragte informieren, Entscheidung: Tiere werden aus 
dem Versuch genommen und getötet. 
20 und 
höher 
Abbruchkriterien:  
Gesamtscore: 
Einzelscore:  
45 und 
höher 
20  
3.2.1.10 Euthanasia in mice 
For euthanasia by CO2, the animals were placed in a plastic container. 6 Litres of CO2 
per minute was introduced in this container for a successful euthanasia.  
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3.2.2 Molecular biology  
3.2.2.1 Protein extraction and quantification 
Mice were euthanized by CO2 and different CNS tissues (spinal cord, brain stem, 
cortex, cerebellum, hippocampus, rest of the brain) were separated. Tissues were 
homogenized in lysis buffer (150 mM NaCl, 10% glycerol, 20 mM Tris HCl, 1% NP40, 
1 mM EDTA, 0.01% sodium azide) with a  tissue rupture (Qiagen Instruments, 
Hombrechtikon, Switzerland). The lysates were centrifuged at 4°C for 45 minutes at 
14000 rpm and supernatant was collected. The concentration of protein was estimated 
using BCA assay/Bradford assay as manufacturer instructions (Pierce® BCA Protein 
Assay Kit, Thermo Scientific, IL, USA). The original protein was diluted 1:10 and 25 
µl of diluted protein were taken in triplicates in a 96 well flat bottom ELISA plate and 
200 µl of Reaction Reagent (Pierce) was added and incubated for 30 minutes at 37 °C. 
The plate was measured in an ELISA reader at the nanometer range of 540 nm. 
Measured protein level was normalized to 2 µg/µl concentrations in the lysis buffer 
with 6X loading dye and stored at -20 °C for further use.  
3.2.2.2 SDS-PAGE and western blot 
Protein loading buffer 6x was added to 30 µl of protein sample (60 µg) and cooked for 
6 minutes at 96 °C. Normalized protein was loaded and separated by 10% SDS-PAGE 
(Rotiphorese® Gel 30, 10x SDS-PAGE, Carl Roth Gmbh, Karlsruhe, Germany), 
transferred (Trans Blot, semi dry transfer cell, BioRad) to a nitrocellulose membrane 
(GE Healthcare, AmershamTM Hybond ECL, Buckinghamshire, UK) and blocked with 
5% BSA for 1.5 hours. Membranes were further incubated overnight at 4°C with the 
primary antibodies diluted in 1x TBST buffer and washed with TBST for 10 minutes 
for 3 times. Membranes were then incubated for 2 hours at 4°C with the secondary 
antibody diluted in 1x TBST followed by 3 times TBST wash for each 5-10 mins. The 
membranes were developed using Super Signal West Pico chemiluminescent substrate 
(Thermo, Pierce Biotechnology, Rockford, IL, USA) in Fusion Fx7 chemiluminescence 
system (PEQLAB, Erlangen, Germany). GAPDH was used as a loading control; 
proteins were analyzed by use of the Fusion Bio1D software (PEQLAB, Erlangen, 
Germany).   
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3.2.2.3 RNA isolation 
The total RNA was isolated using the PEQLAB RNA isolation kit (VWR International 
GmbH, Erlangen, Germany). RNA lysis buffer T was added according to the weight of 
each tissue and the samples were homogenized with Tissue ruptor (Qiagen Instruments, 
Hombrechtikon, Switzerland). The lysates were transferred to DNA removing columns 
placed in a 2.0 ml collection tube and centrifuged at 14000 rpm for 1 min at room 
temperature. Equal volumes of 70% ethanol were added to the lysates and mixed 
thoroughly by vortexing. Lysates were added to the PerfectBind RNA columns in a 
new 2.0 ml collection tube and centrifuged at 14000 rpm for 1 min; the flow through 
was discarded. 500µl of Wash buffer I was added to PerfectBind RNA column and 
placed in a new 2.0ml collection tube, centrifuged at 14000rpm for 15 sec. The flow 
out was discarded and 600µl of Wash buffer II was added and centrifuged at 14000rpm 
for 15 sec. The centrifugation was repeated to dry the column without adding any more 
buffers. The column was placed in new PCR grade 1.5ml tube and 50-100µl of sterile 
dH2O was added directly to the binding matrix. The column was centrifuged for 1 min 
at 5000g to elute RNA.   
3.2.2.4 cDNA synthesis 
cDNA synthesis was done using the QuantiTect® Reverse Transcription Kit (Qiagen 
GmbH, Hilden, Germany) from 1 µg/ml of total RNA. 1 µg/ml of total RNA was 
diluted in 20 µl of water, to this 3 µl genomic DNA wipeout buffer was added and 
incubated at 42 °C for 2 minutes. Then 4 µl 5x RT buffer, 1 µl RT Primer, 1 µl RT 
master mix was added followed by incubation at 42 °C for 30 minutes and at 95 °C for 
3 minutes. The synthesized cDNA was stored at -20°C for further use. 
3.2.2.5 Real time-PCR quantification 
Relative quantification of gene expression in the spinal cord and spleen tissues were 
measured using iTaqTM Universal SYBR® Green qPCR Master Mix (Bio-Rad, CA, 
USA) at 40 cycles at an annealing temperature according to specific various primers in 
the StepOne® Real-Time PCR system (Applied Biosystems, Darmstadt, Germany). 
Primers were designed by NCBI nucleotide primer designing tool and primers were 
synthesized in Eurofins-Genomics (Eurofins MWG Synthesis Gmbh, Ebersberg, 
Germany). The quantification of target genes was done using the listed primers (Table 
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3.1.7) and the PCR reaction mixture of 10 µl Mastermix (iTaqTM Universal SYBR® 
Green), 1 µl forward primer and reverse primer, 7 µl H2O and 1 µl of cDNA. GAPDH 
was used as the internal control gene and the comparative ∆∆CT method (∆CT= target 
gene - housekeeping gene; ∆∆CT = 2^-∆CT) was used to evaluate the relative 
quantification of gene expression. 
3.2.3 Histopathology and immunohistochemistry 
3.2.3.1 Mice Perfusion 
MK2-/- mice and WT mice was anaesthetized by an intraperitoneal injection of ketamine 
(100 mg/kg body weight) and xylazin (20 mg/kg body weight). Transcardial perfusion 
with 4% paraformaldehyde was performed in mice at day 16 (acute phase) and day 60 
(chronic phase) after EAE induction. The spinal cord and brain tissues were removed 
and embedded in paraffin blocks. Tissue processing starts by placing them in 70% 
ethanol for 1 hour, followed by 95% ethanol (95% ethanol/5% methanol) for 1 hour. 
Then they were transferred for the first time in absolute ethanol for 1 hour and for the 
second time in absolute ethanol for 1½ hours. This is followed by 2 more soakings in 
absolute ethanol for 2 hours each. The tissues are then transferred to the first clearing 
agent (Xylene) for 1 hour and a second soak in xylene for 1 hour again. First soak in 
the wax at 58°C for 1 hour and second soak in the wax at 58°C 1 hour. These tissues 
were sectioned into 1µm thick slices and were fixed onto glass slides for histopathology 
and immunohistochemistry.  
3.2.3.2 Histology 
Paraffin sections were evaluated for inflammatory infiltrates (hematoxylin and eosin 
stain), demyelination (Luxol fast blue/periodic acid-Schiff stain) and axonal density 
(Bielschowsky staining). Histological evaluation was done with a light microscope 
(Carl Zeiss, Germany). 
3.2.3.3 Hematoxylin and Eosin staining (H & E) 
Inflammation in the spinal cord in acute and chronic EAE was analyzed by H & E 
staining. Slides were placed in 60°C for the wax to melt overnight, the next day slides 
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were incubated in xylene for deparafinization followed by ethanol (100% ethanol, 96% 
ethanol and 70% ethanol; 2 mins each) hydration. Then slides were stained in 
Hematoxylin for 5 minutes, washed with water and then stained in eosin for 5 minutes. 
After this the slides were rinsed in 96% ethanol and 100% ethanol for dehydration. This 
was followed by 10 mins in first xylene and in second xylene; slides were mounted 
with mounting medium with a glass cover slip.  
3.2.3.4 Luxol fast blue/periodic acid-schiff stain (LFB / PAS) 
Demyelination in spinal cord following EAE was analyzed by LFB/PAS staining. 
Slides were placed in 60°C for the wax to melt overnight, next day the tissue sections 
were deparafinized with xylene and then hydrated in ethanol (100% ethanol, 96% 
ethanol and 70% ethanol;2 minutes each) followed by overnight incubation in luxol fast 
blue stain at 56°C. The glass slide holder was sealed tightly as the stain tends to 
evaporate fast in such conditions. After a few rinses in dH2O and 70% ethanol the slides 
were counter stained in crystal violet for 30-40 seconds. The slides were again shortly 
rinsed in dH2O and dehydrated (96% ethanol and 100% ethanol). Sections were 
mounted with mounting medium in glass cover slip. The final % value for 
demyelination was calculated using equation shown below:   
Demyelinated area (%) =
Demyelinated area in white matter
Total white matter area
× 100 
3.2.3.5 Bielschowsky (Silver staining) 
Axonal density in the spinal cord tissue was analyzed by Bielschowsky-silver staining. 
Deparafinized and hydrated (100% ethanol, 96% ethanol and 70% ethanol; 2 minutes 
each) sections were incubated in dark with 20% silver nitrate (AgNO3) for 20 minutes. 
This is usually used as a stock solution (typically 20% w/v), which must be stored in a 
dark place. The reaction was stopped with a water wash. Then the sections were 
incubated for 2 minutes in 2% Na-Thiosulfate (Sigma Aldrich): 2 gm. of sodium 
thiosulfate in 100ml of distilled water. This was followed by a water wash. Sections 
were dehydrated in ethanol (96% ethanol and 100% ethanol) and mounted with 
mounting medium and cover glass. 
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3.2.3.6 Immunohistochemistry 
For immunohistochemistry, sections were deparafinized in xylene, hydrated, 
endogenous peroxidase was blocked for 10 minutes with 3% hydrogen peroxide and 
pretreated with citrate buffer (10 mM, pH 6) over 5 minutes for 3 times. Paraffin 
sections were incubated with 10% FCS and stained overnight for activated microglia-
macrophage (Mac 3, clone M3/84, 1:200, Pharmingen, San Diego, CA, USA), activated 
B cells (B220, clone RA3-6B2, 1:200, Pharmingen, San Diego, CA, USA) and T cells 
(CD3, clone CD3-12, 1:150, Serotec, Oxford, UK). Respective secondary antibodies 
(Mac 3-goat anti-rat, 1:100, B220-goat anti-rat 1:200 and CD3 goat anti-rabbit-1:250) 
and avidin-biotin method was used and the signals were detect with DAB. Microscopic 
images were captured using a Zeiss light microscope (Germany) and analyzed using 
the ImageJ software. 
3.2.4 Cell culture experiments 
C17.2 cells were cultured in DMEM + 2 mM Glutamine + 10% FBS. Cells were 
cultured at 37 °C in 5% CO2. Cell line was passaged by 1x PBS wash, the adherent cell 
line was followed by 1% Trypsin at 37 °C for 1 minute incubation.  
3.2.4.1 MK2 inhibition and stimulants used for cell lines 
C17.2 cells 
Transfection in C17.2 cells was done using Lipocalyx Viromer. The Mouse MK2 
siRNA was diluted in buffer F to 11µM concentration. 11µl of this diluted siRNA with 
99µl of the diluted transfectant which gives a final concentration of 1.1µm siRNA in 
complex. This was incubated for 5-10 min at room temperature. 200µl of this complex 
was transferred to each well.  
3.2.4.2 Cell proliferation assay 
Cells were seeded in 96 well plates in a final volume of 100 µl/well (1x105 cells/ml).  
Then the old medium was removed and the cells were incubated for 24 hours with fresh 
medium containing TNF-α (10 ng/ml), SB203580 (1 µg/ml), Glateramer acetate 
(10µg/ml) and their combinations. The readings were taken at 0 hrs, 24 hrs and 48 hrs 
after incubation with these reagents. Then 10 µl of WST-1 reagent (Cell proliferation 
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reagent WST-1, Roche applied science, Indianapolis, IN) was added in each well and 
the assay was carried out as mentioned in the instructions provided by the manufacturer. 
Plates were shaken thoroughly for 1 minute on a shaker and incubated for 4 hours at 
standard cell culture conditions. The colour developed from the soluble formazan dye 
cleaved from the tetrazolium salt WST-1 was measured at an absorbance of 420-480 
nm in an ELISA reader. To calculate proliferation, mean absorbance was calculated 
and background absorbance (medium alone) subtracted from each value. The 
percentage of specific proliferation was quantified using the following calculation: % 
Proliferation = (experimental release / spontaneous release) x 100. 
3.2.4.3 Protein extraction  
Culture medium was removed from the cells after they were 80% confluent then fresh 
medium was added with respective treatments for 2-3 hours. Cells were stimulated with 
10 ng/ml TNF-α and or 10 µl/ml GA with or without MK2 inhibition (1µg/ml 
SB203580) or MK2 transfection. Then medium was removed from the cells and washed 
with cold 1x PBS. Cells were scraped from the flask and centrifuged for 3500 rpm, 15 
minutes at 4 °C. Supernatant was discarded and cell pellets were lysed with lysis buffer 
and incubated in ice for 30 minutes. Cell lysates were centrifuged (14000 rpm) at 4 °C 
for 30 minutes, supernatant were collected and stored at -20 °C until analysis.  
3.2.4.4 Protein quantification and western blot 
Protein quantification (BSA protein assay), SDS-PAGE and western blot procedure 
were followed as described in Section 3.2.2.1 and 3.2.2.2. 
3.2.5 Statistics  
All analyses were performed blinded to the genotype. All mice and samples were 
included into the analysis. Statistical analysis for differences between the genotypes in 
the clinical course, histological data, reverse transcription-PCR and protein data were 
performed using the Unpaired t-tests. Statistical significance was set at P ≤ 0.05. 
Statistical analysis and preparation of graphs was performed using GraphPad Prism 
version 7.00 for Windows (GraphPad Software, San Diego, California, USA). Values 
are expressed as mean ± standard error of mean. P values of * P < 0.05, **P < 0.005, 
***P < 0.001 were considered as significant.  
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4 RESULTS 
4.1 Genotype and phenotype confirmation of MK2 deletion in 
C57BL/6J mice 
MK2-/- mice were generated by Kotlyarov et al (1999). To study the function of MK2 
in mouse biological system, a mutation was introduced by homologous recombination 
in embryonic stem (ES) cells. A neomycin-resistance gene (neo) was inserted into the 
catalytic domain of MK2 i.e. exon encoding subdomains V and VI, thereby introducing 
stop codons in all reading frames. The mutant allele is expected to encode a truncated 
kinase that deletes amino acids 130–383, which are essential for the catalytic activity. 
These ES cells were used to generate mice that carry the MK2 mutation. The MK2
−/− 
mice did not display any obvious behavioral defects; they were viable, fertile and grew 
to normal size. 
 
Figure 7: Strategy applied to mutate the MK2 gene and effect of the mutation on MK2 activity. Structure and partial 
restriction map of the MK2 gene, the targeting vector and the targeted locus. X, XbaI; B, BamHI; S, SacI) The MK2 
sequence motifs encoded by different exons (shown by black boxes) are indicated (roman numerals, catalytic 
subdomains; SH3b- I, Src-homology 3 -binding motif; AI, autoinhibitory motif; C-term, carboxy terminus). The neo 
cassette, which contains in-frame translational termination codons, was inserted into the exon encoding subdomains 
V and VI; the mutant locus is expected to encode a truncated kinase that lacks sequences essential for enzymatic 
activity (Kotlyarov et al., 1999) 
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Figure 8: In the MK2 knockout gel (left panel) mice numbers 51, 52, 53, 54, 56, 59 are the mice with the MK2-/- 
gene. The second gel (right panel) represents the MK3 KO gel where the mice 51, 52, 53, 57, 58, 59, 60 are with 
MK3-/- gene. When put together we have mice 54 and 56, which are the MK2-/- mice. 
4.1.1 Total MK2 was decreased in the MK2-/- mice  
The level of total MK2 was analyzed in spinal cord lysates of control and MK2-/- mice 
in EAE to confirm the knockout efficiency. Total MK2 expression were significantly 
reduced in MK2-/- mice in both acute and chronic EAE (Figure 9). 
 
Figure 9: Total MK2 in acute (n=8) and chronic (n=5) EAE mice spinal cord. Total MK2 was significantly 
decreased in acute EAE (left panel) and chronic EAE (right panel) of the spinal cord. GAPDH act as the internal 
loading control. P values of * P < 0.05, **P < 0.005, ***P < 0.001 were considered as significant. 
4.2 EAE in MK2-/- and control mice 
4.2.1 Clinical scoring 
EAE was induced in 10-12 weeks old MK2-/- and control female mice with the       
MOG35-55 peptide. Mice were scored daily for EAE clinical symptoms.  
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Figure 10: Clinical symptoms of MOG35-55-induced EAE in MK2-/- and control mice. A-J represent tail paralysis 
with mild hind limb weakness. K, L depicts the hind limb paralysis which hinders the walking and strength in mice 
thus shown on the plain surface. 
4.3 Clinical symptoms of MK2-/- mice  
4.3.1.1 Chronic phase EAE 
Mice with MK2 deletion (MK2-/-) and controls were analyzed for their susceptibility to 
MOG35-55 peptide EAE induction. EAE was induced in 12 ten-week-old female       
MK2-/- mice and compared with 11 age- and sex-matched controls. There were no 
significant changes seen in the disease course between MK2-/- mice and control mice 
(Figure 11). Table 3 shows the summary of the EAE score in control and MK2-/- mice.  
The onset of clinical symptoms was from day 9-11 in control and MK2-/- mice.  
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Figure 11: MOG35-55-induced EAE in MK2-/- mice and control mice. The data is from 1 chronic EAE experiment. 
The onset of clinical symptoms was from day 9 in controls in MK2-/- mice.  Milder disease course was found in   
MK2-/- mice from day 10 onwards p.i.  
4.3.1.2 Acute phase EAE 
EAE was induced in 16 ten-week-old female control mice and compared with 14 age- 
and sex-matched MK2-/- mice. The onset of clinical symptoms was from days 9-12 in 
controls and from days 9-11 in MK2-/- mice. During the acute phase I experiment there 
were significant differences in the clinical symptoms of MK2-/- mice and control mice. 
The MK2-/- mice showed reduced clinical signs as compared to control mice (Table 3, 
P ≤ 0.001). There were 3 experimental replicates done for acute phase. In the acute 
phase, second experiment there were 3 ten-week old female MK2-/- mice compared 
with 5 age and sex-matched controls. There were significant differences seen in the 
clinical symptoms between the two groups, with MK2-/- mice showing reduced 
symptoms as in the first acute EAE experiment (P ≤ 0.01) (Table 3). In the third EAE 
experiment, 5 MK2-/- mice were compared with 5 age and sex-matched controls. The 
last EAE experiment was not in similar lines as compared to the first two EAE 
experiments. There were no differences seen between the clinical symptoms of two 
groups of mice (P = n.s). All the three EAE scores were pooled into Figure 12. 
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Figure 12: MOG35-55-induced EAE in MK2-/- mice and control mice. The data is pooled from 3 acute EAE 
experiment. The onset of clinical symptoms was from days 9-12 in controls and from days 9-11 in MK2-/- mice. 
Significantly milder disease course was found in MK2-/- mice, on day 12, 13 and 14 p.i.  
Experiment Mice Number 
Day of 
onset 
Incidence 
Score 
Max 
P-value 
Chronic 
EAE 1 
Control 13 9 100% 3.5 
n.s. 
MK2-/- 13 9 100% 3.5 
Acute EAE 
1 
Control 6 12 100% 3 P ≤ 
0.001 
 MK2
-/- 6 10 100% 2 
Acute EAE 
2 
Control 5 9 100% 3.5 P ≤ 0.01 
 MK2-/- 3 9 66.67% 3 
Acute EAE 
3 
Control 5 11 100% 3 
n.s. 
MK2-/- 5 11 80% 3 
Table 3:  Clinical characteristics of MOG35-55-induced EAE in MK2-/- mice 
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Figure 13: MOG35-55-induced EAE in MK2-/- mice and control mice. The data is pooled from 3 acute EAE and 1 
chronic EAE experiment. The onset of clinical symptoms was from days 9-12 in controls and from days 9-11 in  
MK2-/- mice. Milder disease course was found in MK2-/- mice, on day 12 and 14 p.i.  
As it is clear from the description above, the EAE model of MK2 was not stable. In the 
chronic phase no differences were seen, but in the acute phase statistical significant 
differences were seen. The second acute phase was in similar lines as the first acute 
phase. The last acute phase displayed no differences again.  
The mice from the first and second EAE experiments were used for histology. The mice 
from the first and the third EAE experiments were used for protein and RNA analysis. 
It is important to point this out as the results seen in the histological, protein and mRNA 
analysis depends on the mice taken from the experiments.  
4.3.2 Assessment of inflammation: Cell infiltration of T-cells, B-cells and 
macrophages 
To further investigate underlying mechanisms, MK2-/- mice were assessed for 
susceptibility to inflammation in the spinal cord white matter. Haematoxylin and eosin 
staining was used to evaluate inflammatory index. In the chronic phase no difference 
in inflammation was observed between MK2-/- mice and controls (Figure 14D-F). 
Inflammatory index was reduced in MK2-/- mice as compared to control mice (P ≤ 0.05) 
(Figure 14A-C). 
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Immunohistochemical analysis were performed to further investigate the composition 
of infiltrates in spinal cord EAE lesions. Immunostaining for CD3(+), B220(+) and 
Mac3(+) cells were performed and quantified to analyze cellular infiltrate composition 
in spinal cord white matter lesions. The number of CD3(+) T cells was not affected by 
MK2 deletion in acute EAE (Figure 15A-C) and in chronic stage (Figure 15D-F). In 
the acute phase of EAE Mac3(+) cells were reduced in MK2-/- mice (P = 0.039) (Figure 
17A-C). In the chronic phase of EAE there was no significant difference seen in 
Mac3(+) cells and B220(+) cells in MK2-/- mice (Figure 17D-F, Figure 16D-F). 
Disease 
pathology 
Acute EAE Chronic EAE 
Control MK2-/- P-
value 
Control MK2-/- P-value 
Inflammatory 
index 
8.838 ± 
1.32 
4.208 ± 
0.81 
P = 
0.0181 
6.56 ± 
1.48 
5.78 ± 
1.88 
P = 
0.753 
CD3 (+) T 
cells 
1662 ± 
264.7 
1186 ± 
263.9 
P = 
0.236 
907.8 ± 
111.1 
745.6 ± 
184.7 
P ≤ 
0.473 
B220 (+)  B 
cells 
1049 ± 
303.7 
293.6 ± 
57.9 
P ≤ 
0.056 
533.2 ± 
63.04 
945.8 ± 
180.6 
P ≤ 
0.063 
Mac3 (+) 
Macrophages 
1701 ± 
150.5 
1124 ± 
207 
P ≤ 
0.039 
721.3 ± 
153.2 
760.6 ± 
97.81 
P ≤ 
0.834 
Table 4: Immune cell infiltration in spinal cord of EAE mice. Blinded quantification of immune cell infiltration of T 
cells, B cells and macrophages in spinal cord of controls and MK2-/- mice in acute and chronic EAE. Data are 
presented as mean ± SEM. 
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Figure 14: Histopathological analysis of acute (n=8) and chronic (n=5) EAE (H and E). Inflammatory index in the 
spinal cord sections of acute (A, B and C) and chronic (D, E and F) EAE in controls (A, D) and MK2-/- mice (B, E). 
Representative images of spinal cord sections are shown. The inflammatory index (C and F) was lower in MK2-/- 
mice compared to control. Bar: 200 µm, Data are presented as mean ± SEM. 
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Figure 15: T cell infiltration in acute (n=8) and chronic (n=5) EAE spinal cord. CD3 (+) T cells in white matter 
lesions of spinal cord sections in acute (A, B and C) and chronic (D, E and F) EAE in controls (A, D) and MK2-/- 
mice (B, E). The number of CD3 (+) T cells per mm2 was not significantly different in MK2-/- mice compared with 
controls. Bar: 200 µm, Data are presented as mean ± SEM 
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Figure 16: B cell infiltration in acute (n=8) and chronic (n=5) EAE spinal cord. B220 (+) B cells in white matter 
lesions of spinal cord sections in acute (A, B and C) and chronic (D, E and F) EAE in controls (A, D) and MK2-/- 
mice (B, E). The number of B220 (+) B cells per mm2 was less in MK2-/- mice compared with controls in acute EAE 
(C), though not significant. Bar: 200 µm, Data are presented as mean ± SEM. 
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Figure 17: Macrophage infiltration in acute (n=8) and chronic (n=5) EAE spinal cord. Mac3 (+) Macrophages in 
white matter lesions of spinal cord sections in acute (A, B and C) and chronic (D, E and F) EAE in controls (A, D) 
and MK2-/- mice (B, E). The number of Mac3 (+) macrophage per mm2 was lower in MK2-/- mice compared with 
controls in acute phase EAE (C). Bar: 200 µm, Data are presented as mean ± SEM. 
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4.3.3 Demyelination and axonal density in MK2-/- mice 
Luxol fast blue staining was done to evaluate demyelination. At acute phase, day 16 p.i., 
demyelination was significantly reduced in MK2-/- mice as compared to controls (P ≤ 0.05) 
(Figure 18A-C). In the chronic phase no significant differences in demyelination (P = 0.171) 
were observed between MK2-/- mice and controls. 
Axonal density was evaluated by Bielschowsky staining. In the chronic phase no difference in 
axonal density was observed between MK2-/- mice and controls (Figure 19D-F). At day 16-time 
point, axonal density was higher in MK2-/- mice than in controls (P ≤ 0.05) (Figure 19A-C).  
 
Pathology 
Day 16 
P-
value 
Day 60 
P-
value 
Control    MK2-/- Control    MK2-/- 
Demyelination 
(%) 
88.75 ± 
4.40 
56.42 ± 
12.95 
P = 
0.0211 
17.47 ± 
3.31 
11.86 ± 
1.72 
P = 
0.171 
Axonal density 
(%) 
53.44 ± 
3.08 
68 ± 
5.42 
P = 
0.028 
 35.94 ± 
5.66 
44.6 ± 
5.13 
P = 
0.289 
Table 5: Histopathological analysis of spinal cord from EAE mice. Blinded quantification of demyelination 
(LFB/PAS) and axonal density (silver staining) in spinal cord of controls and MK2-/- mice in EAE. Data are 
presented as mean ± SEM. 
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Figure 18: Histopathological analysis of acute (n=8) and chronic (n=5) EAE (LFB/PAS). Demyelination in the 
spinal cord sections of acute (A, B and C) and chronic (D, E and F) EAE in controls (A, D) and MK2-/- mice (B, E). 
Representative images of spinal cord sections are shown. The percentage of demyelination (F) was lower in MK2-/- 
mice compared to control in chronic EAE. Bar: 200 µm, Data are presented as mean ± SEM. 
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Figure 19: Histopathological analysis of acute (n=8) and chronic (n=5) EAE (Silver staining). Axonal density in 
the spinal cord sections of acute (A, B and C) and chronic (D, E and F) EAE in controls (A, D) and MK2-/- mice (B, 
E). Representative images of spinal cord sections are shown. Percentage of axonal density (C and F) was higher in 
MK2-/- mice compared to control. Bar: 200 µm, Data are presented as mean ± SEM.  
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4.3.4 Pattern of cytokines expression in MK2-/- mice spinal cord 
The role of cytokines as important regulatory elements in immune cell infiltration 
processes has been well established in EAE. To quantify the cytokine pattern, pro-
inflammatory cytokine mRNA was analyzed in the spinal cord in the acute and chronic 
phase of EAE. The mice used for the mRNA analysis did not show a significant 
difference in the clinical scores between control vs MK2-/- mice at day 16. In the acute 
phase MK2-/- mice showed no change in the expression of TNF-α (P = 0.301), IL-17 (P 
= 0.650), iNOS (P = 0.673), IL-1β (P = 0.876) and IL-6 (P = 0.310) compared with 
controls (Figure 20A-E). In the chronic phase no differences in pro-inflammatory 
cytokine expression for TNF-α (P = 0.254), IL-1β (P =0.084), IL-6 (P = 0.6905) and 
IL-17 (P = 0.213) were observed (Figure 20F-J).  
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Figure 20: Gene expression of proinflammatory cytokine levels in the spinal cord of controls and MK2-/- mice in 
acute (n=8) and chronic (n=5) EAE. Findings at the acute phase (A-E) and the chronic phase (F-J) are shown. Data 
are presented as mean ± SEM. 
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4.3.5 The cytokine expression in the spleen of MK2-/- and wild type mice 
Spleen from MK2-/- and controls of acute and chronic EAE mice was isolated and used 
for RNA isolation. The cytokines IL-12, IL-6, IL-17 and TNF-α expression were 
measured. The levels of iNOS were also measured. 
The proinflammatory cytokine TNF-α was significantly reduced in spleen of MK2-/- on 
day 16 p.i. (P = 0.0204); (Figure 21A). IL-12 levels were not detectable in the spleen 
of MK2-/- and control mice in the acute phase. In the chronic phase there were no 
significant changes in the cytokines detected in the spleen of control and MK2-/- mice 
(Figure 21E-H); although there was a trend towards reduced levels of TNF-α (P = 
0.896) and iNOS (P = 0.734) expression (Figure 21E, F).  
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Figure 21: Gene expression of proinflammatory cytokine levels in the spleen of controls and MK2-/- mice in acute 
(n=8) and chronic (n=5) EAE. Findings at the acute phase (A-D) and the chronic phase (E-H) are shown. Data are 
presented as mean ± SEM. 
4.3.6 Myelin protein expression in the spinal cord of MK2-/- and wild type 
mice 
To analyze the effect of MK2 deletion on myelin protein expression, we further studied 
the mRNA levels of MBP, PLP and CNPase in acute and chronic phase EAE. In the 
acute phase the mRNA levels of MBP, PLP and CNPase expression is not regulated in 
MK2-/- mice compared to control (Figure 22A-C). Whereas CNPase expression in 
MK2-/- mice was significantly increased in MOG induced chronic EAE spinal cord (day 
60 p.i, P = 0.0201, Figure 22F), Myelin basic protein and PLP levels were not affected 
in chronic EAE spinal cord in protein (Figure 22B, C).  
The levels of MBP were also analyzed in the spinal cord on protein level of both acute 
and chronic EAE. There were no significant differences seen in the acute and chronic 
EAE (Figure 23).  
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At tissue level the protein levels of MBP were analyzed by MBP staining in both acute 
(Figure 24A-C) and chronic phase (Figure 24D-F) of EAE. In the acute phase the 
difference in MBP levels were not significant (P = 0.117). In the chronic phase there 
was no change seen (P = 0.204) in the protein levels of myelin basic protein.  
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Figure 22: Gene expressions of the myelin proteins in the spinal cord of controls and MK2-/- mice in acute (n=8) 
and chronic EAE (n=5). Findings at the acute phase (A-C) and the chronic phase (D-F) are shown. Data are 
presented as mean ± SEM. 
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Figure 23: MBP expression in acute (n=8) and chronic (n=5) EAE mice spinal cord. GAPDH act as the internal 
loading control. Values are expressed as mean ± standard error of mean. n.s. = not significant. 
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Figure 24: Histopathological analysis of acute (n=8) and chronic (n=5) EAE (MBP staining). MBP expression in 
the spinal cord sections of acute (A, B and C) and chronic (D, E and F) EAE in controls (A, D) and MK2-/- mice (B, 
E). Representative images of spinal cord sections are shown. MBP expression (C and F) did not show significant 
differences between the two groups. Bar: 200 µm, Data are presented as mean ± SEM.  
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4.3.7 The remyelination markers were altered in MK2-/- mice 
To get a clear picture on all the myelination markers, we studied the inhibitors of 
remyelination in the spinal cord of acute and chronic phase EAE. The mRNA levels of 
TGFβ, SEMA3A and LINGO-1 were not detectable in the acute phase of EAE in both 
control and MK2-/- mice (Figure 25A-C). In the chronic phase, LINGO-1 was 
significantly increased in the MK2-/- mice as compared to control mice (P = 0.006). 
There were no differences seen in the levels of TGF-β and SEMA-3A in MK2-/- and 
control mice (Figure 25D, E).  
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Figure 25: Gene expressions of the remyelination inhibitors TGFβ, SEMA3A and Lingo-1 in the spinal cord of 
controls and MK2-/- mice in acute (n=8) and chronic EAE (n=5). Findings in the acute phase (A-C) and the chronic 
phase (D-F) are shown. Data are presented as mean ± SEM 
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4.3.8 CREB phosphorylation was increased in the MK2-/- mice 
It was previously known that immature neurons of adult mice expressed phosphorylated 
CREB (Bender, Lauterborn, Gall, Cariaga, & Baram, 2001; Nakagawa et al., 2002). 
Recently activated CREB is reported to stimulate myelin basic protein (MBP) 
expression and to overcome inhibitors in myelin regeneration (Gao et al., 2004). CREB 
phosphorylation was analyzed at the protein level in spinal cord tissue of control and 
MK2-/- mice. In the acute phase of EAE MK2-/- mice showed increased levels of 
phosphorylated CREB (P = 0.0224) as compared to the control mice (Figure 26). There 
were no changes seen (P = 0.0602) in the levels of phosphorylated CREB in the chronic 
phase EAE (Figure 26).  
Acute EAE Chronic EAE 
 
 
Figure 26: CREB phosphorylation in acute (n=8) and chronic (n=5) EAE mice spinal cord. GAPDH was used as 
the internal loading control. P values of * P < 0.05, **P < 0.005, ***P < 0.001 were considered as significant. 
Values are expressed as mean ± standard error of mean. n.s. = not significant. 
4.3.9 NF-κB phosphorylation is reduced in the MK2-/- mice 
NF-κB pathway is known to be a proinflammatory signaling pathway. NF-κB has a role 
in the expression of proinflammatory genes including cytokines and chemokines. 
Phosphorylation of NF-κB was analyzed at protein level in acute and chronic EAE. In 
the acute phase, phosphorylated NF-κB was significantly reduced (P = 0.0463) in the 
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MK2-/- mice (Figure 27). There were no differences seen in the chronic phase for 
phosphorylated NF-κB (Figure 27). 
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Figure 27: NF-κB phosphorylation in acute (n=8) and chronic (n=5) EAE mice spinal cord. GAPDH act as the 
internal loading control. P values of * P < 0.05, **P < 0.005, ***P < 0.001 were considered as significant. Values 
are expressed as mean ± standard error of mean. n.s. = not significant. 
4.3.10 Levels of Akt and STAT-1 remained unchanged in the MK2-/- mice 
PI3K-Akt pathway is a signal transduction pathway that promotes survival and growth 
in response to extracellular signals.  Spinal cord lysates from acute and chronic EAE 
were analyzed to see the levels of Akt and STAT-1. There were no differences seen in 
the levels of Akt phosphorylation and STAT-1 phosphorylation in acute phase (Figure 
28 left panel).  
In the chronic EAE the phosphorylation of Akt and STAT-1 showed no differences. 
The phosphorylation of STAT-1 was increased but not significantly (P = 0.096)   
(Figure 28).  
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Figure 28: AKT and STAT1 phosphorylation in acute (n=8) and chronic (n=5) EAE mice spinal cord. GAPDH act 
as the internal loading control. P values of * P < 0.05, **P < 0.005, ***P < 0.001 were considered as significant. 
Values are expressed as mean ± standard error of mean. n.s. = not significant. 
4.3.11 Analyzing the growth factor receptor Trk-B in MK2-/- mice 
To study the effect of MK2 ablation in mice, the receptor TrkB was studied at protein 
levels in the acute and chronic phase. In the acute phase TrkB receptor protein 
expression was similar between MK2-/- mice and controls (P = 0.950). In the chronic 
phase TrkB receptor protein remained unchanged in MK2-/- mice (P = 0.112) (Figure 
29).  
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Figure 29: TrkB expression in acute (n=8) and chronic (n=5) EAE mice spinal cord. GAPDH act as the internal 
loading control. P values of * P < 0.05, **P < 0.005, ***P < 0.001 were considered as significant. Values are 
expressed as mean ± standard error of mean. n.s. = not significant. 
4.4 In vitro experiments 
4.4.1 MK2 is required for glatiramer acetate mediated C17.2 neuronal 
cell survival/proliferation 
We hypothesized that MK2 the downstream regulator of p38 can be the potential 
interaction partner of GA involved in neuronal cell survival and proliferation.  
C17.2 mouse neuronal cells and p38 inhibitor SB203580 were used in this study. MK2 
gene was knocked down by siRNA transfection using FlexiTube siRNA Mm_MK2  
(0.3 µM) and VIROMER BLUE. Cells were incubated with SB203580 (2 µg/ml) and 
stimulated with TNF-α (10 ng/ml) and/or GA (10 ng/ml). The MK2/TNF-α signaling 
molecules Akt/STAT3 were analyzed by western blot. Cell proliferation was analyzed 
for the same treatments using the WST assay.  
MK2 knock down in C17.2 cells resulted in a down-regulation of Akt phosphorylation 
and there was no difference on STAT3 phosphorylation. The phosphorylation of Akt 
was increased by GA treatment alone, while there was no effect on STAT3 (Figure 30). 
The combined treatments of MK2 knock down and GA decreased the phosphorylation 
of Akt and STAT3. Cell proliferation of C17.2 was reduced by p38 inhibition while 
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GA treatment alone did not induce a difference in the proliferation of the cells (Figure 
31). 
 
Figure 30: Akt phosphorylation decreases after MK2 inhibition. PSTAT3 is down regulated after GA treatment in 
MK2 knockdown C17.2 cells. 
 
Figure 31: WST   proliferation   assay   shows   decreased proliferation after P38 inhibition as compared to 
Glatiramer acetate treatment. 
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5 DISCUSSION 
In the present study the in vivo function of MK2 was characterized using a complete 
gene knockout in mice. Knowing that MK2 is essential for TNF-α biosynthesis we 
hypothesized that knocking out MK2 will lead to a milder disease course. We found 
that MK2 does not affect the disease course of EAE. 
The pathological analysis of acute EAE showed decreased macrophage infiltration, 
myelin and axon degeneration in MK2-/- mice. There were few differences seen in 
chronic EAE such as an increase of the inhibitor of remyelination Lingo-1 and an 
increase in the levels of CNPase mRNA levels.  
5.1 MK2 knockout mice have a normal phenotype  
The p38 MAPK pathway is known to be activated by heat shock, ultraviolet light, 
bacterial lipopolysaccharide (LPS) or pro-inflammatory cytokines like TNF-α or IL-
1β (Freshney et al., 1994; Han et al., 1994; Rouse et al., 1994). After the failure of 
p38 MAPK inhibitors in clinical trials, MK2 was unveiled as a potential target to 
regulate inflammatory cytokines mRNA stability and translation. It is possible to 
determine the physiological function of MK2 in vivo by introducing a targeted 
mutation into the mouse MK2 gene. MK2-/- mice show increased stress resistance and 
survive LPS-induced endotoxic shock (Kotlyarov et al., 1999). MK2-/- mice grew to 
normal size, were fertile and did not display any noticeable behavioral changes as 
compared to its C57BL/6J background control mice.  
Mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MAPKAPK-2 
or MK2) is a downstream substrate of the p38 MAPK responsible for the signaling 
pathways for inflammation, apoptosis and cell motility. In addition, MK2 is a 
prominent kinase that phosphorylates heat shock protein 27 (Hsp27), an intensively 
investigated biomarker of cancer progression (Gurgis, Ziaziaris & Munoz, 2014). In 
experimental asthma, MK2 knockout mice showed less airway inflammation because 
of reduced vascular permeability of the blood-lung-barrier (Gorska et al., 2007).  
In the MPTP mouse model for Parkinson’s disease, MK2-deficient mice show reduced 
neuroinflammation and less degeneration of dopaminergic neurons in the substantia 
nigra; particularly by reducing the production of the neurotoxic substances like TNF-α 
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and nitric oxide (Thomas et al., 2008). MK2- deficient mice exhibited a better Rotarod 
performance as compared with WT mice.  The development of typical Parkinson’s 
disease symptoms like tremor, slow movement, stiffness and poor balance were 
reduced in MK2- deficient mice. 
In the KA-induced animal model of seizure disorder, the role of MK2 was investigated. 
After injection of KA, a reduced degeneration of neurons in the hippocampus of MK2 
deficient mice was found when compared with wild type mice. As the role of MK2 in 
inflammation is well known, the observed neuroprotection was a secondary effect due 
to diminished inflammation in MK2-deficient mice (Thomas, Hitti et al., 2008). 
5.2 EAE in MK2-/- mice 
MK2-/- and C57BL/6J mice were analyzed for EAE symptoms. There was one chronic 
phase EAE study done till day 59 and then three acute phase EAE studies till day 16.  
The first EAE study to be analyzed was conducted till day 59. There were no significant 
differences seen in the disease course between control and MK2-/- mice. Next we 
analyzed the first acute EAE experiment. Here a significant difference was seen in the 
disease course between control and MK2-/- mice from days 14-16 (P ≤ 0.001). The 
second acute EAE study showed a significantly different disease course from days 12-
16 (P ≤ 0.01). The last acute EAE study, however, showed no significant difference 
between the disease course of control and MK2-/- mice. The onset of clinical symptoms 
for all the EAE experiments was on similar days.  
It is also known that there are many factors responsible for the variability in the EAE 
disease course. Some of the causes known for the variability between experiments are: 
Sex and age related differences, variability caused by environment and seasons, early 
weaning increase susceptibility to disease (Papenfuss et al., 2004; Teuscher et al., 
2004); whereas gentling decreased susceptibility (Laban et al., 1995). In addition, 
sound stress increased disease susceptibility (Laban et al., 1994).  
Sex and age does not matter in our case as all female mice were used, they were all 
aged between 10-12 weeks, and these were kept in a stable environment. 
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5.3 Decreased inflammation and infiltration of immune cells  
In the acute phase of EAE, the impaired MK2 signaling led to reduced inflammation. 
Inflammatory infiltrates were present as both aggregated and in a more diffused form. 
In the acute phase, lymphocytes aggregated around the blood vessels in the spinal cord 
white matter in a typical sleeve-shape. Lymphocyte infiltration could still be seen 
during the chronic phase, but this was reduced to some extent compared with that at the 
acute stage. H&E staining also revealed that the normal brain and spinal cord structures 
were well preserved. There has been a study done with TNF KO mice, which exhibited 
a delayed disease induction. It was revealed by H&E staining of spinal cord sections 
that there was impaired accumulation of inflammatory cells in the CNS, which was the 
reason behind delayed disease onset. The CNS infiltrates isolated from TNF KO mice 
at this time point contained lower numbers of both CD4+ T cells and CD11b+ myeloid 
cells, compared with their WT counterparts (Kruglov, Lampropoulou, Fillatreau, & 
Nedospasov, 2011). 
In the acute phase of EAE there was a marked reduction in the infiltration of 
macrophages in the spinal cord sections of MK2-/- mice as compared to control mice. 
There were no significant changes observed in the chronic phase of EAE. In TNF KO 
mice the distribution of myeloid cells within the CNS had no apparent effect on the 
localization of inflammatory macrophages (Mac-3+ cells) in CNS tissue during EAE. 
These data altogether indicated that TNF-α is required for initial recruitment of 
inflammatory cells into the CNS and TNF-α does not affect the localization of cells 
later in the disease progression (Kruglov et al., 2011). According to Gold et al. 2006 
macrophages is the dominant effector cell population in the acute phase of EAE. 
Activated macrophages produce a large number of detrimental soluble factors, which 
can induce functional blockade and/or structural damage. Few of these include nitric 
oxide, which is mostly in combination with reactive oxygen species (Redford et al., 
1997). There was another study done by Nikic et al (2011) and they observed that this 
macrophage mediated reactive oxygen and nitrogen species (ROS and RNS) initiated 
axonal degeneration. Then a reduction in the degeneration of axons was noticed when 
these reactive oxygen and nitrogen species were neutralized. Other studies revealed a 
beneficial role of the presence of alternatively expressed macrophages, this lead to 
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reduced EAE severity. Comparative studies done by Berger et al., (1997) demonstrate 
that the major neuropathological symptoms and disease severity was correlated to the 
absolute number of activated macrophages recruited into the CNS parenchyma.  
In animals actively immunized with MOG, there is a sequence of pathogenic T-cell and 
antibody-dependent effector mechanisms. As analyzed by immunohistochemistry done 
on spinal cord sections, there were no significant differences between T-cell infiltration 
between the two groups of MK2-/- mice and control mice. Although, there was a marked 
reduction in T-cell infiltration between acute phase and chronic phase of EAE in control 
mice. MOG induced EAE, where MOG is a unique myelin autoantigen as it induces 
not only an encephalitogenic T-cell response but also a demyelinating response. 
Demyelinating anti-MOG antibodies reinforce disease severity and initiate wide-
ranged demyelination in T-cell-mediated brain inflammation in models of EAE 
(Genain et al., 1995; Linington et al., 1988; Schluesener & Weiner, 1987). 
B-cell infiltration was analyzed in MK2-/- and control mice. B cells play an important 
role in antibody production, modulating immune response through the production of 
cytokines (Barr et al., 2012; Matsushita et al., 2008) and presentation of antigen to T 
cells (Chen & Jensen, 2008). The resulting “cognate” interactions between T and B 
cells specific for the same or physically linked antigen are fundamental to the 
development of most complex immune responses (Phan, Gray & Cyster, 2009; 
Ramiscal & Vinuesa, 2013). After the analysis no significant differences were seen in 
the B-cell infiltration of MK2-/- and control mice.  
5.4 Myelination and axonal density 
Myelin-specific CD4+ T cells are the major components of the autoimmune response 
in EAE. These cells initiate a series of neuroinflammatory events leading to infiltrating 
immune cells (Domingues, Portugal, Socodato, & Relvas, 2016). This results in an 
attack on myelin-producing oligodendrocytes, which ultimately leads to demyelination 
followed by axonal damage (Bauer et al., 2009; Nicol et al., 2015). It is also known that 
when TNF-α was knocked out from the mice resulted in prolonged confinement of 
activated T cells in the secondary lymphoid organs, leading to severe disease symptoms 
(Kassiotis & Kollias, 2001). 
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Further analysis of myelin proteins revealed reduced demyelination by LFB-PAS 
staining in MK2-/- mice in both acute and chronic phase. The results were pointing 
towards a reduction of total myelin proteins in MK2-/- mice in both acute and chronic 
EAE. It has been earlier reported that in the CNS of MOG-induced EAE-rodents there 
is widespread demyelination (Storch et al., 1998) along with MOG-reactive T-cells 
(Iglesias et al., 2001). In mice lacking TNF-α only in T cells, EAE was induced and 
milder disease severity was seen in comparison to WT animals. Decreased 
demyelination was visualized by Luxol fast blue staining of spinal cord sections 
correlated with milder disease severity in T-TNF KO mice compared with WT animals 
(Kruglov et al., 2011). In TNF-α KO mice there was an overall delay in the onset of the 
disease but later the disease was severe and associated with widespread perivascular 
inflammation in the CNS, but primary demyelination appeared to be reduced overall 
(Körner et al., 1997). 
Bielschowsky silver impregnation for axons revealed a huge loss of axons in the 
demyelinated areas, but axons were preserved in the myelinated areas. Since 
demyelination further leads to axonal damage, this resulted in almost identical 
lesions. It has been known before that in rodents with MOG-induced EAE, axonal 
damage is not only present in the active lesions of white matter, but also in the normal 
white and grey matter (Herrero-Herranz, Pardo, Gold & Linker, 2008; Kornek et al., 
2000). 
It has been reported that high prevalence of axonal damage in the CNS of EAE-rodents 
appears to involve direct damage induced by cytotoxic T-cells and myelin 
autoantibodies (Lassmann, 2010).  
5.5 Cytokine levels 
Cytokines are secreted signaling proteins that play an important role in regulating 
immune responses in EAE. Cytokines provide cell signals both in the immune system 
and CNS compartment, but interestingly, some have detrimental effects in the immune 
system while having beneficial effects in the CNS compartment. Cytokines were 
detected in spinal cord mRNA and spleen mRNA with the help of real-time PCR. There 
were no differences detected in the levels of TNF-α, iNOS, IL-17, IL-6 or IL-1b. The 
levels of TNF-α, IL-6, IL-1b were almost non-detectable in the acute phase of EAE, 
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while this was not true for the chronic phase of EAE. There have been other EAE 
studies, which show non-detectable levels of cytokines after induction. Recent studies 
where cytokine expression in antigen presenting cells in the CNS of mice with severe 
EAE was investigated by Wlodarczyk et al (2014). They had CD45high CD11c+ cells 
express higher level of IL-1β, IL-6 and IL-23. Whereas, in contrast to CD11c− 
microglia, the expression of IL-6 and IL-23 in CD11c+ microglia was undetectable.  
However, the levels of iNOS reduced dramatically between the acute and chronic phase 
of EAE. It has been reported that IL-17 may work in cooperation with other 
proinflammatory cytokines, such as IL1 and TNF-α, to activate iNOS transcription by 
astrocytes (Trajkovic et al., 2001). There have been other reports suggesting that IL1-
induced astrocyte activation causes NO production and contributes to neuronal damage 
(Colombo et al., 2012). 
There was an increase in the levels of IL-1b in MK2-/- mice when compared between 
the acute phase and chronic phase of EAE.  IL-1β is a protein produced by activated 
macrophages to mediate series of effects that range from proliferation to apoptosis. Due 
to this variant signaling, IL-1β plays multiple pathogenic roles in EAE. The importance 
of IL-1β is highlighted by the significant reduction in disease severity during EAE in 
IL-1β receptor KO mice (Sutton, Brereton, Keogh, Mills, & Lavelle, 2006).  
In spleen mRNA cytokines were also checked using RT-PCR. There was a significant 
reduction in the level of TNF-α in the acute phase of EAE, while the levels were almost 
similar in chronic EAE. TNF-α is a transmembrane or a soluble protein that can signal 
as a homotrimer while it is membrane bound (tmTNF-α) or in a soluble form once it is 
proteolytically cleaved by metalloprotease TNF-α converting enzyme (Beutler & 
Cerami, 1989). Activated macrophages and T cells are a major source of TNF-α, also 
several other cell types, including brain resident cells, are capable of producing it as 
well. TNF-α signaling mediates cell death through activating one or more of the three 
classic pathways: nuclear factor NF-кB, mitogen activated protein kinase (MAPK) and 
caspases (Aggarwal et al., 2005; Darnay & Aggarwal, 1997). Other cytokines like 
iNOS, IL-17, IL-6 showed no significant changes. IL-12 was not detected in the spleen 
samples. 
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5.6 NF-kB protein level  
When talking about inflammation, key molecules also include transcription factors such 
as NF-κB, apart from the inflammatory cytokines discussed above such as IL-1β, IL-6 
and TNF-α (Karin, 2006; Langowski et al., 2006; Voronov et al., 2003; Yu, Pardoll, & 
Jove, 2009). IL-1, IL-6, TNF-α and the related receptor activator of NF-κB ligand 
(RANKL) have long been known to affect multiple steps in the dissemination and 
inflammation cascade (Giavazzi et al., 1990; Luo et al., 2007; Mantovani, Allavena, 
Sica, & Balkwill, 2008). Recent reports have indicated that pathways leading to NF-κB 
activation and NO production in astrocytes contribute to MS pathology (Colombo et 
al., 2012; Colombo & Farina, 2012; Farina, Aloisi, & Meinl, 2007). 
Protein levels in the spinal cord lysates showed significant reduction in the expression 
of NF-κB protein in the acute phase of EAE. There were no differences seen in the 
chronic phase of EAE between control and MK2-/- mice. In both cellular contexts, NF-
κB operates downstream after sensing of microbes or tissue damage by the toll-like 
receptor (TLR)-MyD88 pathway, the inflammatory cytokines TNF-α and IL-1β and 
downstream of tissue damage that results in release of alarm signals. NF-κB induces 
the expression of inflammatory cytokines, adhesion molecules, key enzymes in the 
prostaglandin synthase pathway, like (COX2) and nitric oxide (NO) synthase.  
It has been shown in several disease models that the NF-κB pathway plays a role in 
astrocytes by sustaining scar formation, neuroinflammation and neurodegeneration 
(Brambilla et al., 2009; Raasch et al., 2011); thus, its blockade is beneficial and limits 
tissue damage. Similar in the lines we have reports which say that astrocyte-restricted 
ablation of IL-17 signaling impairs NF-κB activation and ameliorates EAE (Kang et 
al., 2010).  
5.7 Phosphorylation of CREB 
Oligodendrocytes (OLGs) are a major cellular component of white matter, which are 
the myelin-forming cells in the brain. There are increased levels of cyclic adenosine 
monophosphate (cAMP) response element binding protein (CREB) in developing 
oligodendrocytes (C. Sato-Bigbee, Chan, & Yu, 1994). Previous experiments, which 
imply inhibition of CREB synthesis, have indicated that CREB is one of the mediators 
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of cAMP-dependent stimulation of OLG differentiation (Carmen Sato-Bigbee & 
DeVries, 1996). 
The activation of CREB has been associated with signaling proteins such as MAPKs 
(Shin et al., 2003) as well as pro-inflammatory cytokines, including IFN-γ and TNF-α 
(Renno et al., 1994; Tanuma et al., 1997). CREB is a potential in vivo substrate for the 
MAPK pathway. In EAE lesions phosphorylation of CREB occurs in the inflammatory 
cells, astrocytes and neurons; this corresponds to the increased phosphorylation of 
MAPKs (Shin et al., 2003). Increased phosphorylation of CREB occurs in the spinal 
cord in the peak stage of EAE and contributes to the activation of inflammatory cells 
such as macrophages. This partially works in the generation of neuropathic pain during 
the course of rat EAE and possibly in human multiple sclerosis (Kim et al., 2007). 
In our study spinal cord lysates showed significantly increased levels of CREB 
phosphorylation in MK2-/- mice in the acute phase of EAE. There were no significant 
differences seen in the chronic phase of EAE suggesting that MK2-/- played a role in 
CREB phosphorylation only in the early stages of the disease. Many reports suggest 
the role of cAMP in the maturation of oligodendrocytes, in the expression of myelin 
basic protein (MBP), P2, P0, proteolipid protein (PLP) and myelin-associated 
glycoprotein (MAG) (Anderson & Miskimins, 1994; Bharucha et al., 1993; Jensen et 
al., 1993). As noticed in the analyses the level of MBP also indicate a pattern towards 
increased levels in the acute phase of EAE. There are results in the similar pattern with 
histological data where the amount of demyelination indicated by LFB-PAS was 
significantly reduced in the acute phase of MK2-/- mice. Further we will discuss the 
increase in myelin basic protein mRNA. Nevertheless is it now known that CREB is an 
important mediator of myelination and cell process outgrowth in OLGs (Carmen Sato-
Bigbee & DeVries, 1996; Wegner, 2000). 
5.8 Regulation of myelin proteins and inhibitors of remyelination  
The myelin sheath is a major element of the white matter of the CNS, facilitating signal 
conduction in axons being its main function. Myelin has a unique molecular 
architecture and is highly specialized. It has a higher proportion of lipids (70-85%) as 
compared to the protein proportion (15-30%) (Morell P, 1999). It contains an array of 
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proteins such as proteolipid protein (PLP), myelin basic protein (MBP), 2,3-cyclic 
nucleotide 3-phosphodiesterase (CNPase), myelin-associated glycoprotein (MAG) and 
myelin oligodendrocyte glycoprotein (MOG). PLP and MBP constitute the majority of 
the total myelin proteins of about 70% (Baumann & Pham-Dinh, 2001, Morell P, 1999). 
CNPase is a specific enzyme localized in the cytoplasm of non-compacted myelin. We 
analyzed the mRNA levels of MBP, PLP and CNPase by RT-PCR. There was a trend 
towards increased levels of MBP mRNA in both acute and chronic phase of EAE of 
MK2-/- mice, but not significant. Furthermore, we analyzed expression of 2,3-cyclic 
nucleotide-3-phosphohydrolase (CNPase), an enzyme specifically expressed in myelin 
and located in oligodendrocyte (Sospedra & Martin, 2005). The protein exists in two 
splice variants and constitutes 3-4% of total myelin protein. The levels of CNPase 
mRNA were significantly increased in the MK2-/- mice of chronic phase of EAE. The 
significant increase in the CNPase levels in the chronic phase cannot be associated to 
be beneficial for the MK2-/- mice.  
Myelin sheath plays an indispensable role in signal conduction. Repeated loss of myelin 
may cause axonal injury that eventually leads to progressive functional deficits. 
Remyelination is the process where new myelin sheaths are created on demyelinated 
axons. 
A molecule that correlates with the extent of oligodendrocyte maturation and 
myelination is Lingo-1, a transmemberane protein containing leucine-rich repeats 
expressed in neurons and oligodendrocytes (Carim-Todd et al., 2003). It is generally 
believed that Lingo-1 negatively regulates oligodendrocyte differentiation and 
myelination in vivo (Mi et al., 2005) and in vitro (Mi et al., 2007). The expression of 
Lingo-1 has been shown to increase diseases of CNS, such as spinal cord injury and 
MS (Mi et al., 2004); the overexpression of Lingo-1 also inhibits myelin formation 
(Bradl & Lassmann, 2010). Deletion of Lingo-1 exhibit increased remyelination, 
functional recovery from EAE and even low EAE scores (Mi et al., 2007). In our study 
Lingo-1 was significantly increased in MK2-/- mice in the chronic phase of EAE. There 
were no differences seen in the acute phase of EAE though, if compared the expression 
of Lingo-1 increased by almost 2-folds from the acute phase to the chronic phase EAE 
in MK2-/- mice. This increase in the expression of Lingo-1 can be associated to have a 
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deteriorating effect on the chronic phase of EAE.  
5.9 Role of MK2 in glatiramer acetate mediated C17.2 neuronal cell 
proliferation/survival 
The mechanisms involved in glatiramer acetate (GA) treatment in multiple sclerosis are 
not completely understood. Recent work suggested that the proliferation of monocytes 
is controlled by GA activating Akt and MEK/ERK pathways which are involved in cell 
proliferation and survival (Carpintero et al., 2010). GA elevates the proliferation of 
neural precursor cells (NPC) (Aharoni, 2014). Recent studies have shown that MK2 is 
crucial for STAT3 activation in response to LPS (Ehlting et al., 2011). STAT3 is 
activated by a wide variety of cytokines or growth factors, it translocates to the nucleus 
and regulates proliferation (Simeone-Penney et al., 2008).  
The findings of this study suggest that proliferation/survival of C17.2 is mediated by 
the MK2 associated with decreased STAT3/Akt activation. GA treatment has no effect 
on pSTAT3 so there is no proliferative effect. The combined treatment of MK2-/- and 
GA results in reduced STAT3/Akt activation which shows that MK2 is crucial for cell 
survival/proliferation. These data suggest that MK2 is required to mediate glatiramer 
acetate cell survival/proliferative effect. 
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6 Summary 
Experimental allergic encephalomyelitis (EAE) is an antigen-driven inflammatory 
disease of the central nervous system (CNS), which has many pathological features in 
common with multiple sclerosis. Multiple sclerosis (MS) is an autoimmune, T-cell 
mediated inflammatory and degenerative disease. 
Immunological processes play a major role in contributing to the initiation and 
continuation of the disease. Cytokines are secreted proteins, their role as important 
regulatory elements in the immune responses has been well established in EAE. TNF-
α is found at high levels in cerebral spinal fluid (CSF) and active lesions of MS patients, 
which makes it a critical cytokine. MK2 signaling is known to be crucial for the 
biosynthesis of cytokines like TNF-α and IL-6, hence influencing the inflammatory 
responses. Yet, the role of MK2 signaling in MS and EAE is poorly understood. 
Hypothesizing that MOG35-55EAE will cause milder symptoms in MK2 depleted mice, 
we performed EAE studies with MK2-/- mice. No phenotypic changes were observed 
in MK2-/- mice. The MK2-/- mice showed milder symptoms of MOG35-55EAE on day 
12 and day 14 along with reduced inflammation and infiltration of macrophages, 
reduced total myelin loss and axonal loss and reduced TNF-α levels. CREB 
phosphorylation was increased in the acute phase along with reduced levels of 
phosphorylated NF-κB. In the chronic phase of EAE, the mRNA levels of CNPase and 
Lingo-1 increased significantly. Taken together, our findings indicate that MK2 does 
not play a major role for in the pathology of MOG35-55EAE. There were regulations 
associated with the acute phase while there was no pattern seen in the chronic phase.  
EAE model is often associated with variability; we also saw some variability between 
the studies. It can be safe to express thereafter that MK2 might not serve as a potential 
target in the treatment of EAE model. 
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6 Zusammenfasung 
Experimentelle autoimmune Enzephalomyelitis (EAE) ist eine Antigen-vermittelte 
entzündliche Erkrankung des zentralen Nervensystems (ZNS), die viele pathologische 
Merkmale der Multiplen Sklerose (MS) zeigt. MS ist eine autoimmune T-Zell-
vermittelte und degenerative Erkrankung des ZNS. 
Immunologische Prozesse spielen eine wichtige Rolle bei der Induktion und 
Pathogenese. TNF-α ist in hohen Konzentrationen im Liquor und aktiven Läsionen von 
MS-Patienten nachzuweisen. Der MK2-Signalweg ist für die Biosynthese von 
Zytokinen wie TNF-α und IL-6 relevant.  Die Rolle des MK2-Signalwegs in MS und 
EAE ist weitgehend unbekannt.  
Unsere Hypothese war die, dass in der MOG35-55EAE bei MK2-defizienten Mäusen zu 
milderen Symptomen kommt. MK2-/- Mäuse zeigten aber nur an Tag 12 und Tag 14 
nach  EAE Induktion mildere Symptome als Kontrollen.  Bei den MK2-defizienten 
Mäusen fand sich eine verminderte Infiltration von Makrophagen, ein geringere 
Schädigung des Myelins und weniger axonale Degeneration. CREB-Phosphorylierung 
war in der akuten Phase erhöht, das phosphorylierte NF-κB  war vermindert. In der 
chronischen Phase der EAE zeigten sich mRNA-Werte von CNPase und Lingo-1 
signifikant erhöht. Zusammengefasst zeigte sich, dass MK2 in der Pathologie von 
MOG35-55EAE keine wesentliche Rolle spielt.  Es gibt Hinweise für eine Wirkung in 
der akuten Phase, nicht aber in der chronischen Phase der EAE.  Die Variabilität von 
EAE Verläufen, wie sie dies in dieser Studie zu beobachteten war, ist bekannt. Eine 
Hemmung von MK2 scheint keine Behandlungsoption für Patienten mit MS 
darzustellen. 
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